Fame Host (https://fame.so) Power to the Patients https://podcasts.fame.so/power-to-the-patients https://feeds.fame.so/power-to-the-patients Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation. Looking for a clinical trial? Visit us at www.withpower.com 315762 en Fri, 29 Aug 2025 14:06:59 +0000 Tue, 14 Apr 2026 14:52:00 +0000 https://content.fameapp.so/uploads/4j14kx7q/52605060-b5ac-11f0-bed6-258e90688a4f/52605220-b5ac-11f0-bd2a-99fd8c119543.jpg Power to the Patients https://podcasts.fame.so/power-to-the-patients Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation. Looking for a clinical trial? Visit us at www.withpower.com Brandon Li Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation. Looking for a clinical trial? Visit us at www.withpower.com No No episodic Brandon Li Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation. Looking for a clinical trial? Visit us at www.withpower.com Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation. Looking for a clinical trial? Visit us at www.withpower.com Brandon Li team@fame.so No No No Precision Medicine Got Kidney Disease Wrong—Until Now https://podcasts.fame.so/e/r874vkqn-precision-medicine-got-kidney-disease-wrong-until-now Precision Medicine Got Kidney Disease Wrong—Until Now 25 No No k08ynqx1 Explore how variant functionalization is driving the future of mechanism-driven medicines as host Brandon interviews Jason Coloma, CEO of Maze Therapeutics, on Power to the Patients. Jason explains why most gene-disease associations fail to become therapies, how APOL1-mediated kidney disease reveals the power of precision nephrology, and what it actually takes to build an integrated genetics-to-drug-discovery platform.
Kidney disease affects 37 million people and is now the ninth leading cause of death globally. Yet despite its scale and severity, it has largely been absent from the precision medicine revolution that reshaped oncology.


In this episode of Power to the Patients, Jason Coloma, CEO of Maze Therapeutics, explains how his team is applying genetics-driven precision medicine to kidney disease by moving beyond statistical associations to true mechanistic understanding.


Jason describes the limits of genome-wide association studies when they stop at correlation, and why understanding the functional impact of specific gene variants is essential for successful drug discovery. At Maze, this approach led to uncovering the pathogenic mechanism behind APOL1-mediated kidney disease, a condition that disproportionately affects Black communities, presents earlier in life, progresses more aggressively, and does not respond to current standard therapies.


Finally, Jason addresses the current state of AI in biotech, where natural language processing and structure-prediction tools accelerate workflows but do not replace cryo-EM, x-ray crystallography, or experienced drug hunters.


What You’ll Learn:

  • Why most genetic associations fail to translate into medicines
  • How variant functionalization enables mechanism-driven drug discovery
  • The biological mechanism behind APOL1-mediated kidney disease
  • Why dialysis outcomes highlight the urgency for disease-modifying therapies
  • How to identify which diseases are suitable for genetics-driven platforms
  • The operational infrastructure required to implement precision nephrology
  • Where AI meaningfully improves drug discovery workflows and where it does not


About the Guest:

Jason Coloma is Chief Executive Officer of Maze Therapeutics, where he leads the company’s mission to transform drug discovery through genetics-driven precision medicine. A trained scientist with deep experience in drug discovery, Jason previously held leadership roles at Genentech and Roche, including Head of Business Development focused on oncology and research technology platforms.


He later served as a venture partner at Third Rock Ventures, where he worked on early-stage biotech formation before building Maze Therapeutics. Under his leadership, Maze has developed a platform centered on variant functionalization to generate mechanism-based therapies for genetically defined diseases.



Episode Resources:

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 01 Apr 2026 12:00:00 +0000 Brandon Li Brandon Li 2533 Explore how variant functionalization is driving the future of mechanism-driven medicines as host Brandon interviews Jason Coloma, CEO of Maze Therapeutics, on Power to the Patients. Jason explains why most gene-disease associations fail to become therapies, how APOL1-mediated kidney disease reveals the power of precision nephrology, and what it actually takes to build an integrated genetics-to-drug-discovery platform. Explore how variant functionalization is driving the future of mechanism-driven medicines as host Brandon interviews Jason Coloma, CEO of Maze Therapeutics, on Power to the Patients. Jason explains why most gene-disease associations fail to become therapies, how APOL1-mediated kidney disease reveals the power of precision nephrology, and what it actually takes to build an integrated genetics-to-drug-discovery platform. No No Why Dr. Ken Sharlin Believes Most Neurological Diseases Are Reversible https://podcasts.fame.so/e/x8y7v2k8-why-dr-ken-sharlin-believes-most-neurological-diseases-are-reversible Why Dr. Ken Sharlin Believes Most Neurological Diseases Are Reversible 24 No No l04r6qz0 In this episode of Power to the Patients, host Brandon Li sits down with Dr. Ken Sharlin, neurologist, researcher, and clinical trial investigator, to explore how precision medicine, functional neurology, and emerging technologies are redefining what’s possible in neurodegenerative disease care. Dr. Sharlin challenges the traditional disease-centered model and shares why restoring biological balance - rather than simply managing symptoms, may unlock new pathways for prevention, reversal, and personalized treatment in conditions like MS, Alzheimer’s, and Parkinson’s.
In this episode of Power to the Patients, Brandon Li speaks with Dr. Ken Sharlin, a neurologist and principal investigator with decades of experience across clinical practice, functional medicine, and clinical research. Dr. Sharlin shares his journey from traditional academic neurology to a systems-based, precision medicine approach that focuses on restoring homeostasis rather than treating diagnoses in isolation.


The conversation explores why lifestyle, environment, and behavioral change play a central role in neurodegenerative disease and how advances in biomarkers, prognostics, and AI-driven diagnostics are transforming how clinicians understand and manage conditions like multiple sclerosis, Alzheimer’s disease, and Parkinson’s. Dr. Sharlin explains how tools such as blood-based biomarkers, disease activity scores, and predictive testing can help tailor therapies to the individual rather than relying on trial-and-error prescribing.


Brandon and Dr. Sharlin also dive into the realities of running clinical trials in a crowded therapeutic landscape, the challenges of patient recruitment when effective treatments already exist, and why sponsors must rethink timelines, communication, and study design. 

What You'll Learn:
- Why most neurodegenerative diseases are driven by lifestyle and environmental factors - not just genetics


- How restoring biological homeostasis can lead to symptom improvement and potential disease reversal


- The difference between diagnostic, prognostic, and predictive biomarkers and why all three matter


- How precision medicine is changing treatment selection in multiple sclerosis and beyond


- Why behavioral change is foundational to functional and integrative neurology


- The role of emerging technologies like neuromodulation, photobiomodulation, sound, and electromagnetic therapies


- What sponsors often underestimate when designing and launching clinical trials


- Why patient recruitment is becoming harder in MS despite therapeutic advances


- How AI and biomarker-driven tools can accelerate drug development and trial execution


- Dr. Sharlin’s vision for the next 10 years of neurological care and research



About the Guest:

Dr. Ken Sharlin is a board-certified neurologist, clinical researcher, and leader in neurological disease reversal. With over 25 years of experience, his peer-reviewed research shows that cognitive decline and early Alzheimer’s disease can be improved and in some cases reversed through personalized, systems-based care.


He integrates conventional neurology, precision medicine, functional medicine, and regenerative therapies to treat conditions including Alzheimer’s, multiple sclerosis, Parkinson’s disease, ALS, epilepsy, and chronic migraine. Dr. Sharlin is the founder of the Sharlin Health Neuroscience Research Center, where he leads Phase II–IV clinical trials for next-generation neurotherapeutics, and the creator of the Brain Tune Up! Protocol.


His work focuses on improving brain health, resilience, and quality of life by addressing neurological disease at its root causes.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 18 Mar 2026 16:20:00 +0000 Brandon Li Brandon Li 2274 In this episode of Power to the Patients, host Brandon Li sits down with Dr. Ken Sharlin, neurologist, researcher, and clinical trial investigator, to explore how precision medicine, functional neurology, and emerging technologies are redefining what’s possible in neurodegenerative disease care. Dr. Sharlin challenges the traditional disease-centered model and shares why restoring biological balance - rather than simply managing symptoms, may unlock new pathways for prevention, reversal, and personalized treatment in conditions like MS, Alzheimer’s, and Parkinson’s. In this episode of Power to the Patients, host Brandon Li sits down with Dr. Ken Sharlin, neurologist, researcher, and clinical trial investigator, to explore how precision medicine, functional neurology, and emerging technologies are redefining what’s possible in neurodegenerative disease care. Dr. Sharlin challenges the traditional disease-centered model and shares why restoring biological balance - rather than simply managing symptoms, may unlock new pathways for prevention, reversal, and personalized treatment in conditions like MS, Alzheimer’s, and Parkinson’s. Functional Medicine, Root Cause Medicine, Brain Health, Power To The Patients No No Why Serotonin Isn’t Outdated, Our Thinking Is https://podcasts.fame.so/e/lnqwv2zn-why-serotonin-isn-t-outdated-our-thinking-is Why Serotonin Isn’t Outdated, Our Thinking Is 23 No No 81nvrkn1 In this episode of Power to the Patients, host Brandon Li sits down with Dr. Jacob Jacobsen, neuroscientist and CEO of Evecxia Therapeutics, to challenge some of psychiatry’s most deeply held assumptions. Dr. Seld explains why clinical novelty, not mechanistic novelty, is what truly matters to patients, and how amplifying serotonin synthesis may offer a safer, more scalable path forward for treating depression and OCD.
Psychiatric drug development may be overcomplicating progress while overlooking effective treatments. Brandon Li speaks with Dr. Jacob Jacobsen, neuroscientist and CEO of Evecxia Therapeutics, about why clinical outcomes should matter more than novel mechanisms.


Jacobsen argues that the field’s fixation on discovering entirely new mechanisms has distracted from the real goal: delivering treatments that produce better clinical outcomes for patients. Drawing on decades of human clinical data, he explains how serotonin synthesis amplification builds on well-established biology to enhance the effectiveness of existing antidepressant approaches, rather than replacing them.


The conversation explores why oral, scalable treatments are essential for addressing the massive unmet need in treatment-resistant depression, especially when costly clinic-based therapies reach only a fraction of patients. Jacobsen also breaks down why OCD presents a smarter initial indication for development, with lower placebo response rates, better patient selection, and a clear regulatory gap for next-line therapies.


Brandon and Dr. Jacobsen take a candid look at the structural failures in psychiatric research, including the continued reliance on animal behavioral models that have repeatedly failed to predict human outcomes. Instead,Dr. Jacobsen advocates for a return to human biology, biomarker research, and clinically grounded trial design, approaches that prioritize real-world impact over theoretical elegance.

What You'll Learn:
- Why clinical novelty matters more than mechanistic novelty in psychiatric drug development


- How serotonin synthesis amplification can improve outcomes beyond traditional SSRIs


- The scalability advantages of oral treatments compared to clinic-based therapies like ketamine


- Why OCD is a strategically stronger indication than depression for early clinical development


- How placebo response rates distort psychiatric trial outcomes and how to reduce them


- Why animal models have repeatedly failed psychiatry and continue to slow innovation


- The importance of prioritizing human biology, biomarkers, and real-world clinical data


- How smarter trial design can reduce risk while increasing the likelihood of meaningful results


About the Guest:

Dr. Jacob Jacobsen is a neuroscientist, inventor, and CEO of Evecxia Therapeutics. He is the originator of the serotonin synthesis amplification pharmacological concept and has led seminal cross-disciplinary research in this area. Prior to Evecxia, Jacobsen held research positions at Duke University and Duke–National University of Singapore and spent eight years in pharma-biotech at NeuroSearch and Lundbeck, working on drug discovery and target validation.

Dr. Jacobsen is widely published in leading psychiatry journals, is an inventor on multiple issued and pending patents, and holds a PhD in Neuropharmacology from the University of Copenhagen.


Episode Resources:



Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 11 Mar 2026 12:00:00 +0000 Brandon Li Brandon Li 2449 In this episode of Power to the Patients, host Brandon Li sits down with Dr. Jacob Jacobsen, neuroscientist and CEO of Evecxia Therapeutics, to challenge some of psychiatry’s most deeply held assumptions. Dr. Seld explains why clinical novelty, not mechanistic novelty, is what truly matters to patients, and how amplifying serotonin synthesis may offer a safer, more scalable path forward for treating depression and OCD. In this episode of Power to the Patients, host Brandon Li sits down with Dr. Jacob Jacobsen, neuroscientist and CEO of Evecxia Therapeutics, to challenge some of psychiatry’s most deeply held assumptions. Dr. Seld explains why clinical novelty, not mechanistic novelty, is what truly matters to patients, and how amplifying serotonin synthesis may offer a safer, more scalable path forward for treating depression and OCD. Mental Health Access, Treatment Resistant Depression, Psychiatry Innovation, Power To The Patients No No Who Really Protects Patients in Clinical Trials? With Dr. Lara Shirikjian https://podcasts.fame.so/e/x8vlj5l8-who-really-protects-patients-in-clinical-trials-with-dr-lara-shirikjian Who Really Protects Patients in Clinical Trials? With Dr. Lara Shirikjian 22 No No 70yp28p1 In this episode of Power to the Patients, host Brandon Li sits down with Dr. Lara Shirikjian, Medical Director at CenExel, to explore why operational excellence, not just innovation, drives progress in psychiatric drug development. Drawing on more than two decades of experience in schizophrenia and CNS research, Dr. Shirikjian explains how protocol mastery, direct sponsor communication, and community trust are essential to running high-performing research sites and advancing meaningful psychiatric treatments.
In this episode of Power to the Patients, Brandon Li speaks with Dr. Lara Shirikjian, board-certified psychiatrist and Medical Director at CenExel, about what it truly takes to build effective, ethical, and scalable psychiatric research programs.


Drawing on over 20 years of clinical and research experience, Dr. Shirikjian shares how operational rigor, deep protocol understanding, consistent site execution, and proactive communication directly impacts study quality, placebo response, and patient retention. She explains why schizophrenia trials, in particular, demand thoughtful wraparound support, strong community provider relationships, and clear boundaries between therapeutic care and research participation.


The conversation also explores the often-overlooked operational realities sponsors face, from protocol complexity to CRO bottlenecks, and why direct PI-to-sponsor communication can dramatically accelerate problem-solving. Throughout the episode, Dr. Shirikjian emphasizes that while technology and innovation matter, human judgment, site culture, and ethical responsibility remain irreplaceable in psychiatric research.

What You'll Learn:
- Why operational consistency plays a critical role in minimizing placebo response in psychiatric trials


- How a protocol-first mindset reduces complexity and improves study execution


- Why direct communication between sponsors and principal investigators speeds up issue resolution


- How wraparound services improve retention in schizophrenia research without compromising study integrity


- The importance of planning for post-study patient restabilization before enrollment begins


- How research sites can build trust with community providers and unlock sustainable referral networks


- Why human judgment and site leadership remain essential despite advances in technology and AI


- What sponsors often underestimate about running high-quality psychiatry and CNS trials



About the Guest:

Dr. Lara Shirikjian is a board-certified adult psychiatrist with over two decades of clinical and research experience specializing in schizophrenia, postpartum depression, mood and anxiety disorders, trauma-related conditions, and women’s mental health. She currently serves as Medical Director and Principal Investigator at CenExel CNS / Collaborative Neuroscience Research, where she leads Phase I–IV clinical trials in partnership with global pharmaceutical sponsors.

Dr. Shirikjian has contributed to pivotal research on treatments such as zuranolone for postpartum depression and maintains an active private psychiatry practice. She also serves as Volunteer Clinical Faculty at Harbor UCLA Medical Center, mentoring psychiatry residents and supporting academic training.


Episode Resources:


Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 25 Feb 2026 13:03:00 +0000 Brandon Li Brandon Li 2394 In this episode of Power to the Patients, host Brandon Li sits down with Dr. Lara Shirikjian, Medical Director at CenExel, to explore why operational excellence, not just innovation, drives progress in psychiatric drug development. Drawing on more than two decades of experience in schizophrenia and CNS research, Dr. Shirikjian explains how protocol mastery, direct sponsor communication, and community trust are essential to running high-performing research sites and advancing meaningful psychiatric treatments. In this episode of Power to the Patients, host Brandon Li sits down with Dr. Lara Shirikjian, Medical Director at CenExel, to explore why operational excellence, not just innovation, drives progress in psychiatric drug development. Drawing on more than two decades of experience in schizophrenia and CNS research, Dr. Shirikjian explains how protocol mastery, direct sponsor communication, and community trust are essential to running high-performing research sites and advancing meaningful psychiatric treatments. No No Turning Pain Into Progress: How Sonia Prashar Built a Mission Around Mental Health https://podcasts.fame.so/e/v85jkxrn-turning-pain-into-progress-how-sonia-prashar-built-a-mission-around-mental-health Turning Pain Into Progress: How Sonia Prashar Built a Mission Around Mental Health 21 No No 81q3r691 In this episode of Power to the Patients, Brandon Li and Sonia Prashar, Founder and CEO of AIM Trials, sit down to discuss how hybrid and decentralized clinical trial models are reshaping mental health research. Sonia shares how her personal experience with postpartum depression inspired a mission to reduce patient burden, expand access, and improve data quality, while challenging stigma and outdated research assumptions along the way. In this episode of Power to the Patients, host Brandon Li speaks with Sonia Prashar, Founder and CEO of AIM Trials, about the future of psychiatry research and why patient-centric innovation is no longer optional. Drawing on more than 18 years of clinical research experience across multiple therapeutic areas, Sonia explains how hybrid and decentralized trial designs are expanding access to underserved communities, improving retention, and generating cleaner, more representative data.

Sonia also opens up about her own journey through postpartum depression and cultural stigma, revealing how her lived experience pushed her to build research models that treat patients as people first, not data points. 


What You'll Learn:
- How hybrid and decentralized trial designs reduce patient burden while improving retention and data quality


- Why patient experience and psychological safety are essential to accurate psychiatry data collection


- How lived experience - including postpartum depression and stigma can fuel meaningful research innovation


- Why rural and underserved populations are critical to building diverse and representative study cohorts


- The operational challenges sponsors often overlook when designing protocols


- How AI tools and telehealth can enhance research without replacing human connection


- The role of informed consent conversations in managing placebo response and encouraging honest reporting


- Why failures and setbacks often teach site leaders more than their biggest wins



About the Guest:

Sonia Prashar is the Founder and CEO of AIM Trials, a leading clinical research site specializing in mental health studies across pediatric, adult, and geriatric populations. With more than 18 years of experience spanning drug and medical device research, Sonia has built a reputation for advancing patient-centered, hybrid, and decentralized trial models that expand access, improve retention, and generate more representative data. Her work integrates clinical research, regulatory excellence, and innovative technologies to modernize psychiatry research while reducing patient burden and stigma. 


Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 18 Feb 2026 12:00:00 +0000 Brandon Li Brandon Li 2021 In this episode of Power to the Patients, Brandon Li and Sonia Prashar, Founder and CEO of AIM Trials, sit down to discuss how hybrid and decentralized clinical trial models are reshaping mental health research. Sonia shares how her personal experience with postpartum depression inspired a mission to reduce patient burden, expand access, and improve data quality, while challenging stigma and outdated research assumptions along the way. In this episode of Power to the Patients, Brandon Li and Sonia Prashar, Founder and CEO of AIM Trials, sit down to discuss how hybrid and decentralized clinical trial models are reshaping mental health research. Sonia shares how her personal experience with postpartum depression inspired a mission to reduce patient burden, expand access, and improve data quality, while challenging stigma and outdated research assumptions along the way. Mental Health Matters, Postpartum Depression, Clinical Research, Power To The Patients No No The Synapse Secret: How One Molecule Normalized Brain Activity in Fragile X Patients https://podcasts.fame.so/e/58z723rn-the-synapse-secret-how-one-molecule-normalized-brain-activity-in-fragile-x-patients The Synapse Secret: How One Molecule Normalized Brain Activity in Fragile X Patients 20 No No 81znp541 In this episode of Power to the Patients, Brandon Li sits down with Dr. Craig Erickson, Research Director and Research Endowed Professor at Cincinnati Children’s and Chief Medical Advisor at Spinogenix, to explore how synaptic restoration is revolutionizing treatment for Fragile X, autism, ALS, Alzheimer's, and schizophrenia. From his decades of clinical experience and pioneering work at Spinogenix, Dr. Erickson shares the science behind restoring brain connectivity, the bold early results that surprised even experts, and why this approach could transform outcomes for patients with devastating neurological disorders.
What if the most effective way to treat some of the most devastating brain disorders isn’t by targeting symptoms in isolation, but by repairing the brain’s most fundamental unit of communication itself?

In this episode of Power to the Patients, host Brandon Li sits down with Dr. Craig Erickson, Research Director and Research Endowed Professor at Cincinnati Children’s and Chief Medical Advisor at Spinogenix, to explore how synaptic dysfunction serves as a unifying biological thread across conditions as diverse as Fragile X Syndrome, autism, schizophrenia, ALS, and Alzheimer’s disease.



Dr. Erickson shares how decades of failed large-scale neuroscience trials led him to rethink the drug development playbook - shifting from subjective clinical scales to objective, quantitative biomarkers like EEG and computer-based cognitive testing. Through his work with Spinogenix, he explains how early-phase trials can now detect true brain target engagement in small patient populations, dramatically reducing placebo effects, timelines, and patient burden.


The conversation dives deep into breakthrough Fragile X data, where a single dose of a synapse-targeting therapy normalized pathological brain activity - an effect stronger than anything previously observed in early trials. Dr. Erickson also unpacks why restoring synaptic connectivity can unlock functional gains that truly matter to patients and families, from reduced anxiety to greater independence and improved quality of life.

Whether you're a patient, caregiver, clinician, or investor seeking to understand the future of brain-targeted medicine, this conversation reveals how precision neuroscience is delivering hope where traditional approaches have failed.

What You'll Learn:
- Why synaptic dysfunction is a common biological endpoint across neurodevelopmental, neurodegenerative, and psychiatric disorders, despite vastly different underlying causes


- How objective biomarkers like EEG and computer-based testing can derisk early-phase clinical trials and outperform subjective symptom scales


- Why a single-dose normalization of gamma band activity in Fragile X represents one of the strongest early target engagement signals ever observed


- How patient stratification and biological enrichment dramatically improve signal detection in heterogeneous conditions like Fragile X and autism


- The difference between using biomarkers for trial derisking and inclusion criteria versus FDA-approvable endpoints and why that distinction matters


- How Spinogenix’s platform uniquely restores synaptic spine morphology, not just neurotransmitter signaling, enabling neurons to regain mature connections


- Why smaller, faster, highly quantitative trials may be the future of neuroscience drug development


- What patients, caregivers, and clinicians should watch for next as synapse-restoring therapies move into chronic dosing and later-stage studies




About the Guest:

Dr. Craig Erickson is a Research Director and Research Endowed Professor at Cincinnati Children’s and Chief Medical Advisor at Spinogenix. For more than 20 years, he has led translational research in neurodevelopmental disorders, focusing on early detection of brain target engagement and patient-specific treatment response in human drug trials. Dr. Erickson holds multiple investigator-initiated INDs, is an inventor on several therapeutic patents, and has received extensive support from the NIH, CDC, U.S. Department of Defense, foundations, and global biotechnology partners.






Episode Resources:


Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 11 Feb 2026 12:00:00 +0000 Brandon Li Brandon Li 2318 In this episode of Power to the Patients, Brandon Li sits down with Dr. Craig Erickson, Research Director and Research Endowed Professor at Cincinnati Children’s and Chief Medical Advisor at Spinogenix, to explore how synaptic restoration is revolutionizing treatment for Fragile X, autism, ALS, Alzheimer's, and schizophrenia. From his decades of clinical experience and pioneering work at Spinogenix, Dr. Erickson shares the science behind restoring brain connectivity, the bold early results that surprised even experts, and why this approach could transform outcomes for patients with devastating neurological disorders. In this episode of Power to the Patients, Brandon Li sits down with Dr. Craig Erickson, Research Director and Research Endowed Professor at Cincinnati Children’s and Chief Medical Advisor at Spinogenix, to explore how synaptic restoration is revolutionizing treatment for Fragile X, autism, ALS, Alzheimer's, and schizophrenia. From his decades of clinical experience and pioneering work at Spinogenix, Dr. Erickson shares the science behind restoring brain connectivity, the bold early results that surprised even experts, and why this approach could transform outcomes for patients with devastating neurological disorders. Neuroscience, Synapses, Brain Health, Neurodegeneration, Power To The Patients No No Beyond Dopamine: Why Traditional Schizophrenia Treatments Miss 50% of Patient Needs https://podcasts.fame.so/e/xn129pj8-beyond-dopamine-why-traditional-schizophrenia-treatments-miss-50-of-patient-needs Beyond Dopamine: Why Traditional Schizophrenia Treatments Miss 50% of Patient Needs 19 No No 703r8l31 In this episode of Power to the Patients, Brandon Li sits down with Dr. Laxminarayan Bhat, Founder and CEO of Reviva Pharmaceuticals, to explore groundbreaking developments in schizophrenia treatment. Dr. Bhat shares insights on his company's innovative drug that shows promising results with fewer side effects and better patient adherence than existing treatments. Discover how their unique approach to targeting serotonin-dopamine signaling, combined with reduced off-target effects, could transform the lives of millions living with schizophrenia. Learn about the challenges and triumphs of developing psychiatric medications, the role of biomarkers in treatment, and the future of precision psychiatry. A groundbreaking approach to treating schizophrenia emerges through innovative drug development that addresses both efficacy and safety concerns in long-term treatment.

In this episode of Power to the Patients, host Brandon Li speaks with Dr. Laxminarayan Bhat, founder and CEO of Reviva Pharmaceuticals, about their revolutionary approach to developing new treatments for schizophrenia, focusing on their lead compound bileroxazine and its promising clinical trial results.

What You'll Learn:
- Why current schizophrenia treatments fall short and how next-generation drugs can better serve patients' lifelong needs

- How rational drug design led to a breakthrough in addressing both serotonin-dopamine signaling and neuroinflammation

- The significance of achieving a 35% discontinuation rate compared to 60-70% with current treatments

- Why targeting multiple symptom domains (positive, negative, and cognitive) is crucial for effective schizophrenia treatment

- How improved drug absorption and metabolism profiles can enhance long-term treatment success

- The role of biomarkers and digital tools in advancing precision psychiatry for schizophrenia

- Why balancing commercial viability with precision medicine remains a key challenge in psychiatric drug development

- How addressing off-target effects can significantly improve drug safety and efficacy profiles



About the Guest:

Dr. Laxminarayan Bhat is the Founder and CEO of Reviva Pharmaceuticals, a pioneering pharmaceutical company focused on developing innovative treatments for psychiatric disorders. With over 25 years of experience in drug discovery and development, Dr. Bhat is a distinguished translational scientist with a PhD in medicinal chemistry and holds over 80 granted patents. He is the inventor of bileroxazine, a breakthrough treatment for schizophrenia that has shown promising results in clinical trials, treating over 1,000 patients with improved efficacy and reduced side effects compared to existing treatments. Under his leadership, Reviva has raised $150 million in funding and developed a novel approach to addressing both the core symptoms of schizophrenia and associated neuroinflammation. His work represents a significant advancement in psychiatric medicine, particularly in developing treatments that offer better patient adherence and reduced discontinuation rates compared to current standards of care.



Episode Resources:


Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 04 Feb 2026 12:00:00 +0000 Brandon Li Brandon Li 1908 In this episode of Power to the Patients, Brandon Li sits down with Dr. Laxminarayan Bhat, Founder and CEO of Reviva Pharmaceuticals, to explore groundbreaking developments in schizophrenia treatment. Dr. Bhat shares insights on his company's innovative drug that shows promising results with fewer side effects and better patient adherence than existing treatments. Discover how their unique approach to targeting serotonin-dopamine signaling, combined with reduced off-target effects, could transform the lives of millions living with schizophrenia. Learn about the challenges and triumphs of developing psychiatric medications, the role of biomarkers in treatment, and the future of precision psychiatry. In this episode of Power to the Patients, Brandon Li sits down with Dr. Laxminarayan Bhat, Founder and CEO of Reviva Pharmaceuticals, to explore groundbreaking developments in schizophrenia treatment. Dr. Bhat shares insights on his company's innovative drug that shows promising results with fewer side effects and better patient adherence than existing treatments. Discover how their unique approach to targeting serotonin-dopamine signaling, combined with reduced off-target effects, could transform the lives of millions living with schizophrenia. Learn about the challenges and triumphs of developing psychiatric medications, the role of biomarkers in treatment, and the future of precision psychiatry. Schizophrenia, Drug Development, Clinical Trials, Neuroscience No No The 20-Year Industry Secret: Redefining Neurodegenerative Treatment https://podcasts.fame.so/e/rn74mky8-the-20-year-industry-secret-redefining-neurodegenerative-treatment The 20-Year Industry Secret: Redefining Neurodegenerative Treatment 18 No No k18ywqm0 In this episode of Power to the Patients, Brandon Li sits down with Dr. Gabriel Vargas, Chief Medical Officer at CuraSen Therapeutics, to explore how targeting the adrenergic system could offer both symptomatic relief and disease-modifying potential for Alzheimer's, Parkinson's, and depression. From his two decades developing breakthrough therapies in neurology and psychiatry, including the migraine treatment Erenumab, Dr. Vargas breaks down translational medicine, challenges the amyloid hypothesis, and reveals why shorter clinical trials may be missing the bigger picture.
What if treating Alzheimer’s, Parkinson’s, and other neurodegenerative diseases requires rethinking the problem entirely - not removing plaques or correcting neurotransmitter deficits, but reactivating the brain’s built-in ability to focus, remember, and repair itself?


In this episode of Power to the Patients, host Brandon Li sits down with Dr. Gabriel Vargas, Chief Medical Officer at CuraSen Therapeutics, to explore how adrenergic system modulators could offer both symptomatic relief and potential disease-modifying effects for neurodegenerative and psychiatric conditions - challenging the dominance of amyloid-focused approaches in Alzheimer's research.


So, whether you're navigating a neurodegenerative diagnosis, curious about innovative drug development, or wondering why current treatments fall short, this conversation is packed with cutting-edge science and hard-won clinical insights. 


What You'll Learn:
- How translational medicine bridges preclinical science and human trials and why it’s essential for determining real-world therapeutic viability


- Why the adrenergic system may unlock both symptomatic improvement and long-term disease-modifying potential for neurodegenerative disorders


- How pairing beta-2 agonists with peripheral beta-blockers enables brain-selective targeting while reducing systemic side effects


- Why direct agonist therapies may succeed where SSRIs and amyloid-focused drugs fall short, especially in severe neurodegenerative states


- The clinical difference between symptomatic relief and true disease modification, and why both matter to patients and caregivers


- How PTRS (Probability of Technical & Regulatory Success) guides strategic decisions, regulatory alignment, and investment in new drug development



About the Guest:

Dr. Gabriel Vargas is Chief Medical Officer at CuraSen Therapeutics and a physician-scientist with over 20 years of experience in early-stage drug development, with particular expertise in neurology and psychiatry. Holding an MD/PhD from UC Irvine, Dr. Vargas has led translational medicine initiatives at industry leaders including Hoffmann-La Roche and Amgen, where he spearheaded the development of Erenumab for migraine - a breakthrough therapy approved by the FDA in 2018. 



Episode Resources:


Power to the Patients is handcrafted by our friends over at: fame.so
]]> Fri, 09 Jan 2026 12:00:00 +0000 Brandon Li Brandon Li 3194 In this episode of Power to the Patients, Brandon Li sits down with Dr. Gabriel Vargas, Chief Medical Officer at CuraSen Therapeutics, to explore how targeting the adrenergic system could offer both symptomatic relief and disease-modifying potential for Alzheimer's, Parkinson's, and depression. From his two decades developing breakthrough therapies in neurology and psychiatry, including the migraine treatment Erenumab, Dr. Vargas breaks down translational medicine, challenges the amyloid hypothesis, and reveals why shorter clinical trials may be missing the bigger picture. In this episode of Power to the Patients, Brandon Li sits down with Dr. Gabriel Vargas, Chief Medical Officer at CuraSen Therapeutics, to explore how targeting the adrenergic system could offer both symptomatic relief and disease-modifying potential for Alzheimer's, Parkinson's, and depression. From his two decades developing breakthrough therapies in neurology and psychiatry, including the migraine treatment Erenumab, Dr. Vargas breaks down translational medicine, challenges the amyloid hypothesis, and reveals why shorter clinical trials may be missing the bigger picture. Alzheimer's, Brain Health, Neurodegeneration, Neuroscience, Power To The Patients No No One Mechanism, Three Conditions: A New Direction in Neurological Treatment https://podcasts.fame.so/e/v85j16yn-why-20m-long-covid-patients-may-finally-have-hope-the-biovie-breakthrough One Mechanism, Three Conditions: A New Direction in Neurological Treatment 17 No No 81q3wv41 What if inflammation was the key to unlocking treatments for Alzheimer's, Parkinson's, and Long COVID? In this episode of Power to the Patients, Brandon Li sits down with Cuong Do, CEO of BioVie, to explore the fascinating intersection of these seemingly unrelated conditions. From diving into medical research at the age of 14 to leading groundbreaking clinical trials, Cuong shares invaluable insights on biotech innovation, trial design, and navigating today's challenging funding landscape. Tune in to discover how a single molecule's unique ability to cross the blood-brain barrier could potentially transform treatment for millions of patients. In this episode, host Brandon Li speaks with Cuong Do, CEO of BioVie, to explore the intersection of inflammation and neurodegenerative diseases. Drawing from his remarkable journey from Vietnam to McKinsey to biotech entrepreneurship, Do shares insights on drug development, clinical trials, and the future of CNS therapeutics.

What You'll Learn:
- Why inflammation may be the hidden link between Alzheimer's, Parkinson's, and Long COVID

- How to design effective clinical trials by minimizing variability and selecting objective endpoints

- The critical advantage of small molecules that can cross the blood-brain barrier

- Why the amyloid hypothesis dominated Alzheimer's research and what we've learned since

- How biotech funding challenges are creating a pipeline problem for future drug development

- The "What Does Success Look Like" framework for maintaining focus on transformative outcomes in drug development

- Why continuous infusion delivery systems can improve safety profiles of existing drugs

- How to evaluate and acquire promising biotech assets through scientific due diligence

- Why Parkinson's trials can be more cost-effective than Alzheimer's studies

- The emerging technologies reshaping CNS drug development, from BBB crossing to personalized oncology

About the Guest:

Cuong Do is the CEO of BioVie, a clinical-stage biopharmaceutical company developing innovative therapies for neurological and inflammatory conditions. With over 17 years as a Senior Partner at McKinsey & Company and executive roles at Samsung, Lenovo, and Merck, he brings extensive leadership experience across healthcare and technology sectors. His journey from conducting medical research at the age of 14 to founding multiple successful biotechnology companies showcases his deep commitment to advancing medical science.


Episode Resources:


Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 03 Dec 2025 12:00:00 +0000 Brandon Li Brandon Li 2128 What if inflammation was the key to unlocking treatments for Alzheimer's, Parkinson's, and Long COVID? In this episode of Power to the Patients, Brandon Li sits down with Cuong Do, CEO of BioVie, to explore the fascinating intersection of these seemingly unrelated conditions. From diving into medical research at the age of 14 to leading groundbreaking clinical trials, Cuong shares invaluable insights on biotech innovation, trial design, and navigating today's challenging funding landscape. Tune in to discover how a single molecule's unique ability to cross the blood-brain barrier could potentially transform treatment for millions of patients. What if inflammation was the key to unlocking treatments for Alzheimer's, Parkinson's, and Long COVID? In this episode of Power to the Patients, Brandon Li sits down with Cuong Do, CEO of BioVie, to explore the fascinating intersection of these seemingly unrelated conditions. From diving into medical research at the age of 14 to leading groundbreaking clinical trials, Cuong shares invaluable insights on biotech innovation, trial design, and navigating today's challenging funding landscape. Tune in to discover how a single molecule's unique ability to cross the blood-brain barrier could potentially transform treatment for millions of patients. No No Why Traditional Psychedelics Miss 90% of Neurology Patients - And The Solution https://podcasts.fame.so/e/1n2rk4xn-why-traditional-psychedelics-miss-90-of-neurology-patients-and-the-solution Why Traditional Psychedelics Miss 90% of Neurology Patients - And The Solution 16 No No 2199x7l1 In this episode of Power to the Patients, Brandon Li sits down with Dr. Chris Witowski, CEO and Co-Founder of Psilera, to explore the fascinating intersection of psychedelics and neurodegeneration. Discover how non-hallucinogenic compounds could revolutionize treatments for conditions like frontotemporal dementia, why traditional psychedelics may have overlooked neurodegenerative applications, and the future of neuroplasticity-based therapies. From biomarker development to innovative drug delivery systems, this conversation offers deep insights into an emerging frontier in neuroscience that could transform patient care beyond traditional psychiatric applications. The future of psychedelic medicine lies in non-hallucinogenic compounds that could revolutionize treatment for neurological conditions while avoiding the complexity of traditional psychedelic therapy.

In this episode of Power to the Patients, host Brandon Li speaks with Dr. Chris Witowski, CEO and Co-Founder of Psilera, to explore the emerging field of non-hallucinogenic psychedelic compounds and their potential applications in treating neurodegenerative conditions, particularly frontotemporal dementia (FTD).


What You'll Learn:
- How non-hallucinogenic compounds could deliver the benefits of psychedelics without the challenges of traditional psychedelic therapy

- Why neurodegeneration presents a unique opportunity for psychedelic medicine, particularly in addressing mood disorders and cognitive decline

- The science behind neuroplasticity and its potential role in treating neurodegenerative conditions

- How biomarkers in neurological conditions provide clearer efficacy measures compared to psychiatric applications

- Why the traditional psychedelic therapy model may not be suitable for neurodegenerative patients

- The potential for combining traditional psychedelics with non-hallucinogenic maintenance doses for optimal patient outcomes

- How new diagnostic tools and blood tests are revolutionizing patient identification in neurodegenerative conditions

- Why the intersection of natural product chemistry and psychedelic medicine creates new therapeutic possibilities




About the Guest:

Dr. Chris Witowski is the CEO and Co-Founder of Psilera, specializing in the development of non-hallucinogenic psychedelic compounds for neurological conditions. With a background in natural products chemistry and a PhD focused on drug discovery from natural sources, he has extensive experience in pharmaceutical development and previously served as Chief Scientific Officer at AltMed. 


Episode Resources:
Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 12 Nov 2025 12:00:00 +0000 Brandon Li Brandon Li 2541 In this episode of Power to the Patients, Brandon Li sits down with Dr. Chris Witowski, CEO and Co-Founder of Psilera, to explore the fascinating intersection of psychedelics and neurodegeneration. Discover how non-hallucinogenic compounds could revolutionize treatments for conditions like frontotemporal dementia, why traditional psychedelics may have overlooked neurodegenerative applications, and the future of neuroplasticity-based therapies. From biomarker development to innovative drug delivery systems, this conversation offers deep insights into an emerging frontier in neuroscience that could transform patient care beyond traditional psychiatric applications. In this episode of Power to the Patients, Brandon Li sits down with Dr. Chris Witowski, CEO and Co-Founder of Psilera, to explore the fascinating intersection of psychedelics and neurodegeneration. Discover how non-hallucinogenic compounds could revolutionize treatments for conditions like frontotemporal dementia, why traditional psychedelics may have overlooked neurodegenerative applications, and the future of neuroplasticity-based therapies. From biomarker development to innovative drug delivery systems, this conversation offers deep insights into an emerging frontier in neuroscience that could transform patient care beyond traditional psychiatric applications. No No Inside the ALS Breakthrough: 20-Year Journey to FDA Approval with Dr. Joseph Palumbo https://podcasts.fame.so/e/28xz5x38-inside-the-als-breakthrough-20-year-journey-to-fda-approval-with-dr-joseph-palumbo Inside the ALS Breakthrough: 20-Year Journey to FDA Approval with Dr. Joseph Palumbo 15 No No 60mkwj40 In this episode of Power to the Patients, Brandon Li and Dr. Palumbo, Chief Medical Officer at BioVie Pharma, explore the evolving landscape of neuroscience research, the critical differences between big pharma and biotech approaches, and promising new pathways for treating conditions like Parkinson's and Alzheimer's. Whether you're a researcher, clinician, or industry professional, this conversation offers a fascinating look at how inflammation-focused treatments and systems biology could revolutionize neurological disease treatment. In this episode of Power to the Patients, host Brandon Li speaks with Dr. Joseph Palumbo, Chief Medical Officer at BioVie Pharma, exploring the fascinating journey from academic research to pharmaceutical development, with a particular focus on neurodegenerative diseases and the crucial role of inflammation-focused treatments in brain health.

What You'll Learn:
- How successful drug development bridges academic research, clinical practice, and commercial strategy

- The key differences between developing drugs in big pharma versus biotech environments

- Why inflammation is emerging as a critical factor in treating neurological conditions like Alzheimer's and Parkinson's

- How to validate early-stage drug development data and make informed decisions about progression

- The evolution of ALS treatment and why smaller, focused trials can lead to breakthrough therapies

- Why systems biology and cross-disciplinary approaches are revolutionizing neuroscience research

- The importance of combining clinical experience with research expertise in drug development

- How natural brain molecules can be modified to create more effective treatments for neurological disorders

- Why understanding the gut-brain connection is crucial for treating neurodegenerative diseases

- The critical role of scientific collaboration and diverse thinking in advancing medical research


About the Guest:

Dr. Joseph Palumbo is the Chief Medical Officer and Head of R&D at BioVie Pharma, bringing extensive expertise in neuroscience, psychiatry, and drug development. With a distinguished career spanning academia (Yale, Cornell, University of Pennsylvania) and pharmaceutical leadership roles at Johnson & Johnson, Mitsubishi, and Cephalon, Dr. Palumbo has been instrumental in developing breakthrough treatments for conditions including ALS, depression, and neurodegenerative disorders. He played a pivotal role in bringing edaravone to market for ALS treatment after a 20-year gap in therapeutic advances. Currently leading research initiatives at BioVie, Dr. Palumbo focuses on inflammation's role in neurological conditions, particularly in Alzheimer's and Parkinson's disease, while exploring innovative approaches to drug development using systems biology and natural brain molecules.


Episode Resources:
Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 05 Nov 2025 12:00:00 +0000 Brandon Li Brandon Li 2396 In this episode of Power to the Patients, Brandon Li and Dr. Palumbo, Chief Medical Officer at BioVie Pharma, explore the evolving landscape of neuroscience research, the critical differences between big pharma and biotech approaches, and promising new pathways for treating conditions like Parkinson's and Alzheimer's. Whether you're a researcher, clinician, or industry professional, this conversation offers a fascinating look at how inflammation-focused treatments and systems biology could revolutionize neurological disease treatment. In this episode of Power to the Patients, Brandon Li and Dr. Palumbo, Chief Medical Officer at BioVie Pharma, explore the evolving landscape of neuroscience research, the critical differences between big pharma and biotech approaches, and promising new pathways for treating conditions like Parkinson's and Alzheimer's. Whether you're a researcher, clinician, or industry professional, this conversation offers a fascinating look at how inflammation-focused treatments and systems biology could revolutionize neurological disease treatment. No No Why Clinical Trial Speed Kills Success - And What Top Sponsors Do Instead ft. Steve Brannan https://podcasts.fame.so/e/qn0vm6vn-why-clinical-trial-speed-kills-success-and-what-top-sponsors-do-instead-ft-steve-brannan Why Clinical Trial Speed Kills Success - And What Top Sponsors Do Instead ft. Steve Brannan 14 No No p1knkzn0 What if you could learn the secrets behind one of psychiatry's most significant breakthroughs in decades? In this episode of Power to the Patients, host Brandon Li sits down with Steve Brannan, Chief Medical Officer of Karuna Therapeutics, to explore the art of clinical trial excellence, the future of precision psychiatry, and the untold story behind developing the first new-mechanism schizophrenia drug in decades. Whether you're a researcher, clinician, or industry professional, this conversation reveals invaluable insights about trial methodology, site relationships, and the delicate balance between speed and quality in drug development. Tune in to discover why clinical operations excellence might be the most underappreciated factor in successful psychiatric drug development. Clinical trial methodology and human relationships are the cornerstones of successful drug development, particularly in psychiatry and neuroscience research.

In this episode of Power to the Patients, host Brandon Li speaks with Dr. Steve Brannan, Chief Medical Officer of Karuna Therapeutics (recently acquired by Bristol Myers Squibb), about the art and science of running successful clinical trials, particularly in psychiatry, and the future of precision medicine in mental health.

What You'll Learn:
- How to build trust-based relationships with research sites to ensure high-quality trial execution
- Why the "right pace" principle in clinical trials matters more than speed
- The framework for detecting and preventing fraudulent trial participants through data monitoring
- How digital biomarkers and AI are reshaping psychiatric clinical trials
- Why successful trial execution depends on balancing hard metrics with "soft touch" site management
- How neuroplasticity-based treatments are changing the paradigm for psychiatric drug development
- The importance of looking beyond traditional biomarkers to digital precision measures in psychiatry
- Why clinical operations excellence is often the overlooked key to trial success
- The emerging role of ecological momentary assessment in capturing real-world patient data
- How to maintain trial quality while scaling across multiple research sites

About the Guest:
Dr. Steve Brannan is the Chief Medical Officer of Karuna Therapeutics, recently acquired by Bristol Myers Squibb, where he played a pivotal role in developing the first new-mechanism schizophrenia drug in decades. With extensive experience as a psychiatrist and clinical researcher, Dr. Brannan has held leadership positions at major pharmaceutical companies including Eli Lilly, Cyberonics, Novartis, and Takeda. His expertise spans clinical trial methodology, neuroimaging, and psychiatric drug development, having been instrumental in bringing several successful medications to market. In this episode, Dr. Brannan shares invaluable insights on clinical trial optimization, the evolution of precision psychiatry, and the critical importance of clinical operations excellence in drug development. His work at Karuna Therapeutics, where he was employee number two, culminated in the successful development and FDA approval of a groundbreaking schizophrenia treatment, demonstrating his deep understanding of both the scientific and operational aspects of psychiatric drug development.

Episode Highlights:
00:00 Intro: Leading Innovation in Psychiatric Drug Development
04:01 The Story Behind Karuna's Breakthrough Schizophrenia Drug
11:23 Navigating Big Pharma vs Biotech: Lessons from Both Worlds 
17:12 The Art of Managing Trial Variance in Psychiatry
26:29 Building Trust Through "Soft Touch" Site Management
37:56 The Promise of Digital Biomarkers in Psychiatric Trials 
46:52 AI's Role in Clinical Development: Opportunities and Limitations
49:47 Neuroplasticity and the Future of Psychiatric Medicine
56:37 Clinical Operations: The Unsung Heroes of Trial Success

Episode Resources:

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Tue, 21 Oct 2025 14:32:00 +0000 Brandon Li Brandon Li 2454 What if you could learn the secrets behind one of psychiatry's most significant breakthroughs in decades? In this episode of Power to the Patients, host Brandon Li sits down with Steve Brannan, Chief Medical Officer of Karuna Therapeutics, to explore the art of clinical trial excellence, the future of precision psychiatry, and the untold story behind developing the first new-mechanism schizophrenia drug in decades. Whether you're a researcher, clinician, or industry professional, this conversation reveals invaluable insights about trial methodology, site relationships, and the delicate balance between speed and quality in drug development. Tune in to discover why clinical operations excellence might be the most underappreciated factor in successful psychiatric drug development. What if you could learn the secrets behind one of psychiatry's most significant breakthroughs in decades? In this episode of Power to the Patients, host Brandon Li sits down with Steve Brannan, Chief Medical Officer of Karuna Therapeutics, to explore the art of clinical trial excellence, the future of precision psychiatry, and the untold story behind developing the first new-mechanism schizophrenia drug in decades. Whether you're a researcher, clinician, or industry professional, this conversation reveals invaluable insights about trial methodology, site relationships, and the delicate balance between speed and quality in drug development. Tune in to discover why clinical operations excellence might be the most underappreciated factor in successful psychiatric drug development. No No Dr. Anantha Shekhar on the Convergence of Psychiatry, Neurology, and the Next Era of Brain Medicine https://podcasts.fame.so/e/286q3wpn-anantha-shekhar-on-the-convergence-of-psychiatry-neurology-and-the-next-era-of-brain-medicine Dr. Anantha Shekhar on the Convergence of Psychiatry, Neurology, and the Next Era of Brain Medicine 13 No No j12rxj51 In this episode of Power to the Patients, Brandon Li speaks with Dr. Anantha Shekhar, Senior Vice Chancellor for Health Sciences and Dean of the School of Medicine at the University of Pittsburgh. Dr. Shekhar shares how his early experiences with a family member’s schizophrenia inspired a lifelong mission to bridge neuroscience, psychiatry, and translational research. They explore how psychiatry and neurology are rapidly converging, why the future of mental health treatment lies in understanding brain circuits and plasticity, and what AI, precision medicine, and synthetic biology might mean for the next generation of therapies. Dr. Shekhar also reflects on his pioneering work developing xanomeline—the first novel mechanism of action for schizophrenia in over 70 years—and offers hard-won lessons on trial design, translational gaps, and maintaining scientific rigor in a complex field. A fascinating conversation on the science—and the humanity—behind reshaping how we understand and treat the brain. Power to the Patients is handcrafted by our friends over at: fame.so]]> Wed, 15 Oct 2025 12:00:00 +0000 Brandon Li Brandon Li 3005 In this episode of Power to the Patients, Brandon Li speaks with Dr. Anantha Shekhar, Senior Vice Chancellor for Health Sciences and Dean of the School of Medicine at the University of Pittsburgh. Dr. Shekhar shares how his early experiences with a family member’s schizophrenia inspired a lifelong mission to bridge neuroscience, psychiatry, and translational research. They explore how psychiatry and neurology are rapidly converging, why the future of mental health treatment lies in understanding brain circuits and plasticity, and what AI, precision medicine, and synthetic biology might mean for the next generation of therapies. Dr. Shekhar also reflects on his pioneering work developing xanomeline—the first novel mechanism of action for schizophrenia in over 70 years—and offers hard-won lessons on trial design, translational gaps, and maintaining scientific rigor in a complex field. A fascinating conversation on the science—and the humanity—behind reshaping how we understand and treat the brain. In this episode of Power to the Patients, Brandon Li speaks with Dr. Anantha Shekhar, Senior Vice Chancellor for Health Sciences and Dean of the School of Medicine at the University of Pittsburgh. Dr. Shekhar shares how his early experiences with a family member’s schizophrenia inspired a lifelong mission to bridge neuroscience, psychiatry, and translational research. They explore how psychiatry and neurology are rapidly converging, why the future of mental health treatment lies in understanding brain circuits and plasticity, and what AI, precision medicine, and synthetic biology might mean for the next generation of therapies. Dr. Shekhar also reflects on his pioneering work developing xanomeline—the first novel mechanism of action for schizophrenia in over 70 years—and offers hard-won lessons on trial design, translational gaps, and maintaining scientific rigor in a complex field. A fascinating conversation on the science—and the humanity—behind reshaping how we understand and treat the brain. No No Ram Mukunda, CEO of IGC Pharma, on Innovation and Hope in Alzheimer’s Care https://podcasts.fame.so/e/rn741jp8-ram-mukunda-ceo-of-igc-pharma-on-innovation-and-hope-in-alzheimer-s-care Ram Mukunda, CEO of IGC Pharma, on Innovation and Hope in Alzheimer’s Care 12 No No k18yr650 In this episode of Power to the Patients, Brandon Li speaks with Ram Mukunda, CEO of IGC, about groundbreaking approaches to Alzheimer’s care. Ram shares how his team is developing an ultra-low dose THC-based therapy to reduce agitation and neuroinflammation without sedation, and how AI models may transform early diagnosis for millions worldwide. Their conversation highlights both the science and the human urgency behind innovating for patients and caregivers facing Alzheimer’s. Power to the Patients is handcrafted by our friends over at: fame.so]]> Tue, 23 Sep 2025 15:23:00 +0000 Brandon Li Brandon Li 2382 In this episode of Power to the Patients, Brandon Li speaks with Ram Mukunda, CEO of IGC, about groundbreaking approaches to Alzheimer’s care. Ram shares how his team is developing an ultra-low dose THC-based therapy to reduce agitation and neuroinflammation without sedation, and how AI models may transform early diagnosis for millions worldwide. Their conversation highlights both the science and the human urgency behind innovating for patients and caregivers facing Alzheimer’s. In this episode of Power to the Patients, Brandon Li speaks with Ram Mukunda, CEO of IGC, about groundbreaking approaches to Alzheimer’s care. Ram shares how his team is developing an ultra-low dose THC-based therapy to reduce agitation and neuroinflammation without sedation, and how AI models may transform early diagnosis for millions worldwide. Their conversation highlights both the science and the human urgency behind innovating for patients and caregivers facing Alzheimer’s. No No Brandon Bentzley, CSO and Co-founder of Magnus Medical, on Precision Psychiatry and Rewiring Depression https://podcasts.fame.so/e/2n6q7q18-brandon-bentzley-cso-and-co-founder-of-magnus-medical-on-precision-psychiatry-and-rewiring-depression Brandon Bentzley, CSO and Co-founder of Magnus Medical, on Precision Psychiatry and Rewiring Depression 11 No No j02rmr20 What if we could treat severe depression in just five days — and give patients back the cognitive control to live their true lives? This week on Power to the Patients, we sit down with Brandon Bentzley, MD, PhD, co-founder and Chief Scientific Officer at Magnus Medical, to talk about the future of precision psychiatry and the breakthrough SAINT™ protocol. Power to the Patients is handcrafted by our friends over at: fame.so]]> Wed, 17 Sep 2025 14:29:00 +0000 Brandon Li Brandon Li 4098 What if we could treat severe depression in just five days — and give patients back the cognitive control to live their true lives? This week on Power to the Patients, we sit down with Brandon Bentzley, MD, PhD, co-founder and Chief Scientific Officer at Magnus Medical, to talk about the future of precision psychiatry and the breakthrough SAINT™ protocol. What if we could treat severe depression in just five days — and give patients back the cognitive control to live their true lives? This week on Power to the Patients, we sit down with Brandon Bentzley, MD, PhD, co-founder and Chief Scientific Officer at Magnus Medical, to talk about the future of precision psychiatry and the breakthrough SAINT™ protocol. No No Sarah MacCallum & Melissa Gaines- Clinical Operations Leaders at Annovis Bio https://podcasts.fame.so/e/58z7p2jn-sarah-maccallum-melissa-gaines-clinical-operations-leaders-at-annovis-bio Sarah MacCallum & Melissa Gaines- Clinical Operations Leaders at Annovis Bio 10 No No 81znrpv1 What does great clinical operations really look like? In this episode, Sarah MacCallum and Melissa Gaines of Annovis Bio share their journeys into clinops and the lessons they’ve learned leading Alzheimer’s and neurology trials. From choosing the right site partners to keeping engagement high, to navigating the unique challenges of working with vulnerable populations, they break down what it takes to run trials that truly make an impact. Power to the Patients is handcrafted by our friends over at: fame.so]]> Wed, 10 Sep 2025 13:25:00 +0000 Brandon Li Brandon Li 3028 What does great clinical operations really look like? In this episode, Sarah MacCallum and Melissa Gaines of Annovis Bio share their journeys into clinops and the lessons they’ve learned leading Alzheimer’s and neurology trials. From choosing the right site partners to keeping engagement high, to navigating the unique challenges of working with vulnerable populations, they break down what it takes to run trials that truly make an impact. What does great clinical operations really look like? In this episode, Sarah MacCallum and Melissa Gaines of Annovis Bio share their journeys into clinops and the lessons they’ve learned leading Alzheimer’s and neurology trials. From choosing the right site partners to keeping engagement high, to navigating the unique challenges of working with vulnerable populations, they break down what it takes to run trials that truly make an impact. No No Daniel O'Connell, CEO of Acumen Pharmaceuticals, on Oligomers, Innovation, and Hope in Alzheimer’s https://podcasts.fame.so/e/1n2r4pyn-daniel-o-connell-ceo-of-acumen-pharmaceuticals-on-oligomers-innovation-and-hope-in-alzheimer-s Daniel O'Connell, CEO of Acumen Pharmaceuticals, on Oligomers, Innovation, and Hope in Alzheimer’s 0 No No 21997mj1 With over 25 years of experience building and investing in CNS companies, Daniel shares the story of why he placed a big bet on Acumen — from its origins as a seed-stage idea to today’s phase 2 clinical trial, Altitude AD. He explains the science behind targeting amyloid beta oligomers (rather than plaques), what makes Alzheimer’s research uniquely difficult, and why recent advances in biomarkers, trial design, and patient recruitment give him hope for meaningful progress.   Power to the Patients is handcrafted by our friends over at: fame.so]]> Fri, 05 Sep 2025 15:19:00 +0000 Brandon Li Brandon Li 2745 With over 25 years of experience building and investing in CNS companies, Daniel shares the story of why he placed a big bet on Acumen — from its origins as a seed-stage idea to today’s phase 2 clinical trial, Altitude AD. He explains the science behind targeting amyloid beta oligomers (rather than plaques), what makes Alzheimer’s research uniquely difficult, and why recent advances in biomarkers, trial design, and patient recruitment give him hope for meaningful progress.   With over 25 years of experience building and investing in CNS companies, Daniel shares the story of why he placed a big bet on Acumen — from its origins as a seed-stage idea to today’s phase 2 clinical trial, Altitude AD. He explains the science behind targeting amyloid beta oligomers (rather than plaques), what makes Alzheimer’s research uniquely difficult, and why recent advances in biomarkers, trial design, and patient recruitment give him hope for meaningful progress.   No No Michael Gold, Chief R&D Officer at Compass Pathways https://podcasts.fame.so/e/0njy6wq8 Michael Gold, Chief R&D Officer at Compass Pathways 0 No No 40pq5lx1 In this episode, Brandon sits down with Dr. Michael Gold, Chief R&D Officer at Compass Pathways, to explore the art and science of running high-quality clinical trials. With nearly 30 years of experience across pharma giants like J&J and GSK, as well as small biotechs, Mike shares a masterclass on clinical operations—why the best study design means nothing without flawless execution, and how quality must always come before speed or cost.  In this episode, Brandon sits down with Dr. Michael Gold, Chief R&D Officer at Compass Pathways, to explore the art and science of running high-quality clinical trials. With nearly 30 years of experience across pharma giants like J&J and GSK, as well as small biotechs, Mike shares a masterclass on clinical operations—why the best study design means nothing without flawless execution, and how quality must always come before speed or cost. 

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Tue, 26 Aug 2025 19:23:38 +0000 Brandon Li Brandon Li 3340 In this episode, Brandon sits down with Dr. Michael Gold, Chief R&D Officer at Compass Pathways, to explore the art and science of running high-quality clinical trials. With nearly 30 years of experience across pharma giants like J&J and GSK, as well as small biotechs, Mike shares a masterclass on clinical operations—why the best study design means nothing without flawless execution, and how quality must always come before speed or cost.  In this episode, Brandon sits down with Dr. Michael Gold, Chief R&D Officer at Compass Pathways, to explore the art and science of running high-quality clinical trials. With nearly 30 years of experience across pharma giants like J&J and GSK, as well as small biotechs, Mike shares a masterclass on clinical operations—why the best study design means nothing without flawless execution, and how quality must always come before speed or cost.  No No Matthew Leoni, CMO of Merida Biosciences, on Navigating the Challenges and Opportunities in Neuroscience Drug Development https://podcasts.fame.so/e/lnqw9l5n Matthew Leoni, CMO of Merida Biosciences, on Navigating the Challenges and Opportunities in Neuroscience Drug Development 0 No No 81nvlw31 Brandon Li talks with Matt Leoni—former Senior VP of Global Clinical Development at Cerevel and now Chief Medical Officer at Merida Biosciences. Matt shares his journey from medical school to leading late-stage drug development in neuroscience. He discusses the unique challenges of neuro drug development, from the subjectivity of endpoints and high placebo response rates to the operational hurdles of large-scale trials. Matt offers candid insights into why promising drugs sometimes fail, the limitations of current measures, and where innovation is most needed. The conversation explores disease-modifying therapies, advances in Parkinson’s and schizophrenia research, the promise and pitfalls of psychedelics and psychoplastogens, and his vision for a more risk-tolerant industry that fosters breakthrough discoveries. Brandon Li talks with Matt Leoni—former Senior VP of Global Clinical Development at Cerevel and now Chief Medical Officer at Merida Biosciences. Matt shares his journey from medical school to leading late-stage drug development in neuroscience. He discusses the unique challenges of neuro drug development, from the subjectivity of endpoints and high placebo response rates to the operational hurdles of large-scale trials. Matt offers candid insights into why promising drugs sometimes fail, the limitations of current measures, and where innovation is most needed. The conversation explores disease-modifying therapies, advances in Parkinson’s and schizophrenia research, the promise and pitfalls of psychedelics and psychoplastogens, and his vision for a more risk-tolerant industry that fosters breakthrough discoveries.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Thu, 14 Aug 2025 15:58:00 +0000 Brandon Li Brandon Li 3377 Brandon Li talks with Matt Leoni—former Senior VP of Global Clinical Development at Cerevel and now Chief Medical Officer at Merida Biosciences. Matt shares his journey from medical school to leading late-stage drug development in neuroscience. He discusses the unique challenges of neuro drug development, from the subjectivity of endpoints and high placebo response rates to the operational hurdles of large-scale trials. Matt offers candid insights into why promising drugs sometimes fail, the limitations of current measures, and where innovation is most needed. The conversation explores disease-modifying therapies, advances in Parkinson’s and schizophrenia research, the promise and pitfalls of psychedelics and psychoplastogens, and his vision for a more risk-tolerant industry that fosters breakthrough discoveries. Brandon Li talks with Matt Leoni—former Senior VP of Global Clinical Development at Cerevel and now Chief Medical Officer at Merida Biosciences. Matt shares his journey from medical school to leading late-stage drug development in neuroscience. He discusses the unique challenges of neuro drug development, from the subjectivity of endpoints and high placebo response rates to the operational hurdles of large-scale trials. Matt offers candid insights into why promising drugs sometimes fail, the limitations of current measures, and where innovation is most needed. The conversation explores disease-modifying therapies, advances in Parkinson’s and schizophrenia research, the promise and pitfalls of psychedelics and psychoplastogens, and his vision for a more risk-tolerant industry that fosters breakthrough discoveries. No No Gerard Sanacora, Professor at Yale, on glutamate, GABA, and the next era of depression treatment https://podcasts.fame.so/e/mn4lyw3n Gerard Sanacora, Professor at Yale, on glutamate, GABA, and the next era of depression treatment 6 No No x06rnv80 Brandon Li talks with Dr. Gerard Sanacora, Professor of Psychiatry at Yale, about his journey from molecular physiology to pioneering research on GABA, glutamate, and rapid-acting antidepressants. Gerard shares how a surprising finding in patients undergoing ECT redirected his research toward depression—and eventually to ketamine. Their conversation explores the science of neuroplasticity, the complexities behind ketamine’s mechanism of action, and how interventional psychiatry and digital tools may shape the future of mental health care. Brandon Li talks with Dr. Gerard Sanacora, Professor of Psychiatry at Yale, about his journey from molecular physiology to pioneering research on GABA, glutamate, and rapid-acting antidepressants. Gerard shares how a surprising finding in patients undergoing ECT redirected his research toward depression—and eventually to ketamine. Their conversation explores the science of neuroplasticity, the complexities behind ketamine’s mechanism of action, and how interventional psychiatry and digital tools may shape the future of mental health care.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Thu, 19 Jun 2025 13:53:41 +0000 Brandon Li Brandon Li 3227 Brandon Li talks with Dr. Gerard Sanacora, Professor of Psychiatry at Yale, about his journey from molecular physiology to pioneering research on GABA, glutamate, and rapid-acting antidepressants. Gerard shares how a surprising finding in patients undergoing ECT redirected his research toward depression—and eventually to ketamine. Their conversation explores the science of neuroplasticity, the complexities behind ketamine’s mechanism of action, and how interventional psychiatry and digital tools may shape the future of mental health care. Brandon Li talks with Dr. Gerard Sanacora, Professor of Psychiatry at Yale, about his journey from molecular physiology to pioneering research on GABA, glutamate, and rapid-acting antidepressants. Gerard shares how a surprising finding in patients undergoing ECT redirected his research toward depression—and eventually to ketamine. Their conversation explores the science of neuroplasticity, the complexities behind ketamine’s mechanism of action, and how interventional psychiatry and digital tools may shape the future of mental health care. No No Backing Breakthroughs in Psychedelics https://podcasts.fame.so/e/q80vwp38 Backing Breakthroughs in Psychedelics 5 No No p0kn8v41 Dina Burkitbayeva, CEO of Freedom Biosciences, shares how she launched one of the first venture funds focused on mental health innovation. After co-founding PsyMed Ventures, she partnered with Dr. John Krystal to advance a more durable version of ketamine for treatment-resistant depression. She discusses the rise of interventional psychiatry, the limitations of current antidepressants, and the evolving clinical landscape for next-gen therapeutics. A powerful look at what it takes to bring meaningful change to mental health treatment. Dina Burkitbayeva, CEO of Freedom Biosciences, shares how she launched one of the first venture funds focused on mental health innovation. After co-founding PsyMed Ventures, she partnered with Dr. John Krystal to advance a more durable version of ketamine for treatment-resistant depression. She discusses the rise of interventional psychiatry, the limitations of current antidepressants, and the evolving clinical landscape for next-gen therapeutics. A powerful look at what it takes to bring meaningful change to mental health treatment.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Fri, 06 Jun 2025 01:06:02 +0000 Brandon Li Brandon Li 2375 Dina Burkitbayeva, CEO of Freedom Biosciences, shares how she launched one of the first venture funds focused on mental health innovation. After co-founding PsyMed Ventures, she partnered with Dr. John Krystal to advance a more durable version of ketamine for treatment-resistant depression. She discusses the rise of interventional psychiatry, the limitations of current antidepressants, and the evolving clinical landscape for next-gen therapeutics. A powerful look at what it takes to bring meaningful change to mental health treatment. Dina Burkitbayeva, CEO of Freedom Biosciences, shares how she launched one of the first venture funds focused on mental health innovation. After co-founding PsyMed Ventures, she partnered with Dr. John Krystal to advance a more durable version of ketamine for treatment-resistant depression. She discusses the rise of interventional psychiatry, the limitations of current antidepressants, and the evolving clinical landscape for next-gen therapeutics. A powerful look at what it takes to bring meaningful change to mental health treatment. No No Joel Raskin, CMO of Arrivo Bio talks about unlocking the future of psychiatry https://podcasts.fame.so/e/p8m790x8 Joel Raskin, CMO of Arrivo Bio talks about unlocking the future of psychiatry 4 No No 70v5wn21 Brandon Li talks with Joel Raskin, Chief Medical Officer at Arrivo, about his journey from training in psychiatry in Toronto to leading pharmaceutical research in his current role. Joel shares details on SP-624, an Arrivo compound showing promise in treating depression through epigenetic mechanisms. Their deep dive covers the challenges of clinical trials, and the potential for precision psychiatry to revolutionize psychiatry and neuroscience. Brandon Li talks with Joel Raskin, Chief Medical Officer at Arrivo, about his journey from training in psychiatry in Toronto to leading pharmaceutical research in his current role. Joel shares details on SP-624, an Arrivo compound showing promise in treating depression through epigenetic mechanisms. Their deep dive covers the challenges of clinical trials, and the potential for precision psychiatry to revolutionize psychiatry and neuroscience.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Fri, 23 May 2025 18:09:41 +0000 Brandon Li Brandon Li 2846 Brandon Li talks with Joel Raskin, Chief Medical Officer at Arrivo, about his journey from training in psychiatry in Toronto to leading pharmaceutical research in his current role. Joel shares details on SP-624, an Arrivo compound showing promise in treating depression through epigenetic mechanisms. Their deep dive covers the challenges of clinical trials, and the potential for precision psychiatry to revolutionize psychiatry and neuroscience. Brandon Li talks with Joel Raskin, Chief Medical Officer at Arrivo, about his journey from training in psychiatry in Toronto to leading pharmaceutical research in his current role. Joel shares details on SP-624, an Arrivo compound showing promise in treating depression through epigenetic mechanisms. Their deep dive covers the challenges of clinical trials, and the potential for precision psychiatry to revolutionize psychiatry and neuroscience. No No Dr. Jerry Rosenbaum & Dr. Sharmin Ghaznavi: Mass General Center on the Neuroscience of Psychedelics https://podcasts.fame.so/e/28xzp208 Dr. Jerry Rosenbaum & Dr. Sharmin Ghaznavi: Mass General Center on the Neuroscience of Psychedelics 3 No No 60mk2m60 In this episode, Dr. Jerry Rosenbaum and Dr. Sharmin Ghaznavi offer a rare look into academia’s role in the psychedelic renaissance, tracing the origins of Mass General’s Center for the Neuroscience of Psychedelics. They discuss how their shared interest in rumination—and its role in treatment-resistant mental illness—led them to explore psilocybin’s effects on brain connectivity. The conversation spans everything from neuroplasticity and default mode networks to the challenges of securing funding, the limits of industry-driven research, and what’s next in training the next generation of psychiatrists. It’s an honest, far-reaching discussion about where the science stands—and where it still needs to go. In this episode, Dr. Jerry Rosenbaum and Dr. Sharmin Ghaznavi offer a rare look into academia’s role in the psychedelic renaissance, tracing the origins of Mass General’s Center for the Neuroscience of Psychedelics. They discuss how their shared interest in rumination—and its role in treatment-resistant mental illness—led them to explore psilocybin’s effects on brain connectivity. The conversation spans everything from neuroplasticity and default mode networks to the challenges of securing funding, the limits of industry-driven research, and what’s next in training the next generation of psychiatrists. It’s an honest, far-reaching discussion about where the science stands—and where it still needs to go.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Mon, 12 May 2025 23:07:09 +0000 Brandon Li Brandon Li 2553 In this episode, Dr. Jerry Rosenbaum and Dr. Sharmin Ghaznavi offer a rare look into academia’s role in the psychedelic renaissance, tracing the origins of Mass General’s Center for the Neuroscience of Psychedelics. They discuss how their shared interest in rumination—and its role in treatment-resistant mental illness—led them to explore psilocybin’s effects on brain connectivity. The conversation spans everything from neuroplasticity and default mode networks to the challenges of securing funding, the limits of industry-driven research, and what’s next in training the next generation of psychiatrists. It’s an honest, far-reaching discussion about where the science stands—and where it still needs to go. In this episode, Dr. Jerry Rosenbaum and Dr. Sharmin Ghaznavi offer a rare look into academia’s role in the psychedelic renaissance, tracing the origins of Mass General’s Center for the Neuroscience of Psychedelics. They discuss how their shared interest in rumination—and its role in treatment-resistant mental illness—led them to explore psilocybin’s effects on brain connectivity. The conversation spans everything from neuroplasticity and default mode networks to the challenges of securing funding, the limits of industry-driven research, and what’s next in training the next generation of psychiatrists. It’s an honest, far-reaching discussion about where the science stands—and where it still needs to go. No No Spyros Papapetropoulos, CEO of Neuphoria https://podcasts.fame.so/e/v85jxwjn Spyros Papapetropoulos, CEO of Neuphoria 2 No No 81q36j31 Spyros Papapetropoulos, a leading neurologist and neuroscientist, joins Power CEO, Brandon Li, to discuss his remarkable career and the transformative work at Neuphoria. Spyros delves into his transition from practicing neurologist to drug development and his decision to focus on neuropsychiatric diseases. They explore Neuphoria's innovative approach to treating social anxiety disorder with their lead program, BNC210, which has shown promising results in reducing anxiety without the side effects of current treatments. Spyros and Brandon discuss unmet needs in psychiatric treatments, the operational challenges in clinical trials, and the evolving landscape of neuroscience - including the exciting advancements in imaging, biomarkers, and precision psychiatry. Spyros Papapetropoulos, a leading neurologist and neuroscientist, joins Power CEO, Brandon Li, to discuss his remarkable career and the transformative work at Neuphoria. Spyros delves into his transition from practicing neurologist to drug development and his decision to focus on neuropsychiatric diseases. They explore Neuphoria's innovative approach to treating social anxiety disorder with their lead program, BNC210, which has shown promising results in reducing anxiety without the side effects of current treatments. Spyros and Brandon discuss unmet needs in psychiatric treatments, the operational challenges in clinical trials, and the evolving landscape of neuroscience - including the exciting advancements in imaging, biomarkers, and precision psychiatry.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Mon, 12 May 2025 22:03:07 +0000 Brandon Li Brandon Li 2537 Spyros Papapetropoulos, a leading neurologist and neuroscientist, joins Power CEO, Brandon Li, to discuss his remarkable career and the transformative work at Neuphoria. Spyros delves into his transition from practicing neurologist to drug development and his decision to focus on neuropsychiatric diseases. They explore Neuphoria's innovative approach to treating social anxiety disorder with their lead program, BNC210, which has shown promising results in reducing anxiety without the side effects of current treatments. Spyros and Brandon discuss unmet needs in psychiatric treatments, the operational challenges in clinical trials, and the evolving landscape of neuroscience - including the exciting advancements in imaging, biomarkers, and precision psychiatry. Spyros Papapetropoulos, a leading neurologist and neuroscientist, joins Power CEO, Brandon Li, to discuss his remarkable career and the transformative work at Neuphoria. Spyros delves into his transition from practicing neurologist to drug development and his decision to focus on neuropsychiatric diseases. They explore Neuphoria's innovative approach to treating social anxiety disorder with their lead program, BNC210, which has shown promising results in reducing anxiety without the side effects of current treatments. Spyros and Brandon discuss unmet needs in psychiatric treatments, the operational challenges in clinical trials, and the evolving landscape of neuroscience - including the exciting advancements in imaging, biomarkers, and precision psychiatry. No No Steve Gourlay, CEO of Actinogen https://podcasts.fame.so/e/xn12l1j8 Steve Gourlay, CEO of Actinogen 1 No No 703rvw31 Steve Gourlay joins Power CEO, Brandon Li, to discuss Actinogen's innovative approach to Alzheimer's treatment. Steven shares his background in clinical trials and drug development, highlighting the potential of the company's lead molecule, Xanamem, a daily pill aimed at reducing brain cortisol levels. Their conversation covers the challenges in Alzheimer's & depression research and the promising early clinical data. Steven sheds insight on the strategic focus on Alzheimer's over depression due to unmet medical needs and the future direction in Alzheimer's research. Brandon and Steven also dive into the regulatory landscape, patient selection criteria, and the broader implications of Actinogen's work in transforming the treatment landscape for neurodegenerative diseases. Steve Gourlay joins Power CEO, Brandon Li, to discuss Actinogen's innovative approach to Alzheimer's treatment. Steven shares his background in clinical trials and drug development, highlighting the potential of the company's lead molecule, Xanamem, a daily pill aimed at reducing brain cortisol levels. Their conversation covers the challenges in Alzheimer's & depression research and the promising early clinical data. Steven sheds insight on the strategic focus on Alzheimer's over depression due to unmet medical needs and the future direction in Alzheimer's research. Brandon and Steven also dive into the regulatory landscape, patient selection criteria, and the broader implications of Actinogen's work in transforming the treatment landscape for neurodegenerative diseases.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Mon, 28 Apr 2025 18:48:41 +0000 Brandon Li Brandon Li 2473 Steve Gourlay joins Power CEO, Brandon Li, to discuss Actinogen's innovative approach to Alzheimer's treatment. Steven shares his background in clinical trials and drug development, highlighting the potential of the company's lead molecule, Xanamem, a daily pill aimed at reducing brain cortisol levels. Their conversation covers the challenges in Alzheimer's & depression research and the promising early clinical data. Steven sheds insight on the strategic focus on Alzheimer's over depression due to unmet medical needs and the future direction in Alzheimer's research. Brandon and Steven also dive into the regulatory landscape, patient selection criteria, and the broader implications of Actinogen's work in transforming the treatment landscape for neurodegenerative diseases. Steve Gourlay joins Power CEO, Brandon Li, to discuss Actinogen's innovative approach to Alzheimer's treatment. Steven shares his background in clinical trials and drug development, highlighting the potential of the company's lead molecule, Xanamem, a daily pill aimed at reducing brain cortisol levels. Their conversation covers the challenges in Alzheimer's & depression research and the promising early clinical data. Steven sheds insight on the strategic focus on Alzheimer's over depression due to unmet medical needs and the future direction in Alzheimer's research. Brandon and Steven also dive into the regulatory landscape, patient selection criteria, and the broader implications of Actinogen's work in transforming the treatment landscape for neurodegenerative diseases. No No Boehringer Ingelheim: Christine Sakdalan and Mike Jablonski talk precision psychiatry https://podcasts.fame.so/e/x8y7z128 Boehringer Ingelheim: Christine Sakdalan and Mike Jablonski talk precision psychiatry 16 No No l04rxlq0 In this episode of Power to the Patients, Boehringer Ingelheim leaders Christine Sakdalan and Mike Jablonski from discuss how precision psychiatry—using tools like biomarkers and neuroimaging—can personalize treatment for conditions like schizophrenia and depression. They highlight the importance of holistic care, digital therapeutics, and industry collaboration to address unmet needs and improve outcomes in mental health. 

In this episode of Power to the Patients, Boehringer Ingelheim leaders Christine Sakdalan and Mike Jablonski from discuss how precision psychiatry—using tools like biomarkers and neuroimaging—can personalize treatment for conditions like schizophrenia and depression. They highlight the importance of holistic care, digital therapeutics, and industry collaboration to address unmet needs and improve outcomes in mental health. 

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 09 Apr 2025 00:37:34 +0000 Brandon Li Brandon Li 2432 In this episode of Power to the Patients, Boehringer Ingelheim leaders Christine Sakdalan and Mike Jablonski from discuss how precision psychiatry—using tools like biomarkers and neuroimaging—can personalize treatment for conditions like schizophrenia and depression. They highlight the importance of holistic care, digital therapeutics, and industry collaboration to address unmet needs and improve outcomes in mental health.  In this episode of Power to the Patients, Boehringer Ingelheim leaders Christine Sakdalan and Mike Jablonski from discuss how precision psychiatry—using tools like biomarkers and neuroimaging—can personalize treatment for conditions like schizophrenia and depression. They highlight the importance of holistic care, digital therapeutics, and industry collaboration to address unmet needs and improve outcomes in mental health.  No No John Krystal: Advancing Ketamine Research & Psychiatry at Yale https://podcasts.fame.so/e/rnklqv38 John Krystal: Advancing Ketamine Research & Psychiatry at Yale 15 No No 70wjqw81 John Krystal, Chair of the Department of Psychiatry at Yale, joins Brandon Li to discuss his groundbreaking work on ketamine's antidepressant effects and the evolving landscape of psychiatric treatments. Dr. Krystal was at the forefront of the discovery of ketamine's rapid antidepressant properties in the 1990s. Dr. Krystal shares insights from his career - his pioneering work on the rapid antidepressant effects of ketamine, exploring its journey from a misunderstood drug to a revolutionary treatment backed by rigorous research, its development into a treatment by Johnson & Johnson, and its dramatic impact on patients. The conversation also explores the future of psychiatric research, addressing the convergence of neurobiology, psychotherapy, and neuromodulation to create more effective, personalized treatments for disorders like schizophrenia and depression. John Krystal, Chair of the Department of Psychiatry at Yale, joins Brandon Li to discuss his groundbreaking work on ketamine's antidepressant effects and the evolving landscape of psychiatric treatments. Dr. Krystal was at the forefront of the discovery of ketamine's rapid antidepressant properties in the 1990s. Dr. Krystal shares insights from his career - his pioneering work on the rapid antidepressant effects of ketamine, exploring its journey from a misunderstood drug to a revolutionary treatment backed by rigorous research, its development into a treatment by Johnson & Johnson, and its dramatic impact on patients. The conversation also explores the future of psychiatric research, addressing the convergence of neurobiology, psychotherapy, and neuromodulation to create more effective, personalized treatments for disorders like schizophrenia and depression.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Fri, 07 Mar 2025 18:58:14 +0000 Brandon Li Brandon Li 3662 John Krystal, Chair of the Department of Psychiatry at Yale, joins Brandon Li to discuss his groundbreaking work on ketamine's antidepressant effects and the evolving landscape of psychiatric treatments. Dr. Krystal was at the forefront of the discovery of ketamine's rapid antidepressant properties in the 1990s. Dr. Krystal shares insights from his career - his pioneering work on the rapid antidepressant effects of ketamine, exploring its journey from a misunderstood drug to a revolutionary treatment backed by rigorous research, its development into a treatment by Johnson & Johnson, and its dramatic impact on patients. The conversation also explores the future of psychiatric research, addressing the convergence of neurobiology, psychotherapy, and neuromodulation to create more effective, personalized treatments for disorders like schizophrenia and depression. John Krystal, Chair of the Department of Psychiatry at Yale, joins Brandon Li to discuss his groundbreaking work on ketamine's antidepressant effects and the evolving landscape of psychiatric treatments. Dr. Krystal was at the forefront of the discovery of ketamine's rapid antidepressant properties in the 1990s. Dr. Krystal shares insights from his career - his pioneering work on the rapid antidepressant effects of ketamine, exploring its journey from a misunderstood drug to a revolutionary treatment backed by rigorous research, its development into a treatment by Johnson & Johnson, and its dramatic impact on patients. The conversation also explores the future of psychiatric research, addressing the convergence of neurobiology, psychotherapy, and neuromodulation to create more effective, personalized treatments for disorders like schizophrenia and depression. No No Next-Gen Treatments for Anxiety and Depression Disorders https://podcasts.fame.so/e/489m67p8 Next-Gen Treatments for Anxiety and Depression Disorders 14 No No v17rq630 In this episode, Brandon sits down with Shawn Singh, CEO of Vistagen, to discuss a first-of-its-kind approach to treating mental health conditions. Vistagen is developing pherines, a new class of nasal spray treatments that work through nose-to-brain neural pathways, with the potential to provide fast-acting relief for conditions like social anxiety disorder and depression—without systemic exposure, weight gain, or addiction risk. Key Takeaways: Mental health treatments haven’t changed in decades. Traditional antidepressants come with slow onset, side effects, and compliance challenges—patients need better options. Vistagen’s pherines offer a completely new approach. These nasal sprays use neural circuits to deliver rapid effects without entering the bloodstream, eliminating common side effects. First-ever Phase 3 success for acute treatment of social anxiety disorder. Vistagen’s lead drug, Fasedienol, showed rapid and significant anxiety reduction in a public speaking challenge study. Non-systemic treatments could change the future of medicine. Unlike traditional pills, pherines don’t require processing through the liver or bloodstream—reducing toxicity and drug interactions. This could be a once-in-a-generation shift in neuroscience. If successful, pherines could reshape treatment standards for mental health and beyond. In this episode, Brandon sits down with Shawn Singh, CEO of Vistagen, to discuss a first-of-its-kind approach to treating mental health conditions. Vistagen is developing pherines, a new class of nasal spray treatments that work through nose-to-brain neural pathways, with the potential to provide fast-acting relief for conditions like social anxiety disorder and depression—without systemic exposure, weight gain, or addiction risk.

Key Takeaways:

  • Mental health treatments haven’t changed in decades. Traditional antidepressants come with slow onset, side effects, and compliance challenges—patients need better options.
  • Vistagen’s pherines offer a completely new approach. These nasal sprays use neural circuits to deliver rapid effects without entering the bloodstream, eliminating common side effects.
  • First-ever Phase 3 success for acute treatment of social anxiety disorder. Vistagen’s lead drug, Fasedienol, showed rapid and significant anxiety reduction in a public speaking challenge study.
  • Non-systemic treatments could change the future of medicine. Unlike traditional pills, pherines don’t require processing through the liver or bloodstream—reducing toxicity and drug interactions.
  • This could be a once-in-a-generation shift in neuroscience. If successful, pherines could reshape treatment standards for mental health and beyond.
Power to the Patients is handcrafted by our friends over at: fame.so
]]> Tue, 25 Feb 2025 18:15:22 +0000 Brandon Li Brandon Li 2701 In this episode, Brandon sits down with Shawn Singh, CEO of Vistagen, to discuss a first-of-its-kind approach to treating mental health conditions. Vistagen is developing pherines, a new class of nasal spray treatments that work through nose-to-brain neural pathways, with the potential to provide fast-acting relief for conditions like social anxiety disorder and depression—without systemic exposure, weight gain, or addiction risk. Key Takeaways: Mental health treatments haven’t changed in decades. Traditional antidepressants come with slow onset, side effects, and compliance challenges—patients need better options. Vistagen’s pherines offer a completely new approach. These nasal sprays use neural circuits to deliver rapid effects without entering the bloodstream, eliminating common side effects. First-ever Phase 3 success for acute treatment of social anxiety disorder. Vistagen’s lead drug, Fasedienol, showed rapid and significant anxiety reduction in a public speaking challenge study. Non-systemic treatments could change the future of medicine. Unlike traditional pills, pherines don’t require processing through the liver or bloodstream—reducing toxicity and drug interactions. This could be a once-in-a-generation shift in neuroscience. If successful, pherines could reshape treatment standards for mental health and beyond. In this episode, Brandon sits down with Shawn Singh, CEO of Vistagen, to discuss a first-of-its-kind approach to treating mental health conditions. Vistagen is developing pherines, a new class of nasal spray treatments that work through nose-to-brain neural pathways, with the potential to provide fast-acting relief for conditions like social anxiety disorder and depression—without systemic exposure, weight gain, or addiction risk. Key Takeaways: Mental health treatments haven’t changed in decades. Traditional antidepressants come with slow onset, side effects, and compliance challenges—patients need better options. Vistagen’s pherines offer a completely new approach. These nasal sprays use neural circuits to deliver rapid effects without entering the bloodstream, eliminating common side effects. First-ever Phase 3 success for acute treatment of social anxiety disorder. Vistagen’s lead drug, Fasedienol, showed rapid and significant anxiety reduction in a public speaking challenge study. Non-systemic treatments could change the future of medicine. Unlike traditional pills, pherines don’t require processing through the liver or bloodstream—reducing toxicity and drug interactions. This could be a once-in-a-generation shift in neuroscience. If successful, pherines could reshape treatment standards for mental health and beyond. No No Precision Psychiatry and Emerging Technologies https://podcasts.fame.so/e/x8vlpy78 Precision Psychiatry and Emerging Technologies 13 No No 70ypw451 In this episode, Brandon Li sits down with Dr. Jordan Smoller - Jerrold F. Rosenbaum Chair in Psychiatry at Mass General, Co-Director for the Center for Suicide Research and Prevention at MGH and Harvard, Director of the Center for Precision Psychiatry, and a professor at Harvard Medical School, to explore the future of psychiatry. They discuss how AI, big data, and genomics are transforming mental health care—bringing us closer to precision psychiatry that moves beyond trial-and-error treatment. Dr. Smoller shares his journey from early psychiatric research to leading one of the foremost centers in precision psychiatry, tackling some of the biggest challenges in mental health. Key topics include: The promise of precision psychiatry – Why psychiatry has lagged behind other fields in precision medicine, and how AI and genomics are closing the gap. AI in suicide prevention – How electronic health records and machine learning models could predict suicide risk for earlier intervention. Rethinking antidepressant treatment – Why 50% of patients don’t respond to their first antidepressant, and how predictive modeling could reduce trial-and-error prescribing. Drug development breakthroughs – How genomics and AI are identifying new targets for psychiatric drug development and improving clinical trial success rates. Digital tools & biomarkers – The role of wearables, vocal biomarkers, and real-world data in improving diagnosis, treatment selection, and monitoring. In this episode, Brandon Li sits down with Dr. Jordan Smoller - Jerrold F. Rosenbaum Chair in Psychiatry at Mass General, Co-Director for the Center for Suicide Research and Prevention at MGH and Harvard, Director of the Center for Precision Psychiatry, and a professor at Harvard Medical School, to explore the future of psychiatry. They discuss how AI, big data, and genomics are transforming mental health care—bringing us closer to precision psychiatry that moves beyond trial-and-error treatment.

Dr. Smoller shares his journey from early psychiatric research to leading one of the foremost centers in precision psychiatry, tackling some of the biggest challenges in mental health.

Key topics include:

  • The promise of precision psychiatry – Why psychiatry has lagged behind other fields in precision medicine, and how AI and genomics are closing the gap.
  • AI in suicide prevention – How electronic health records and machine learning models could predict suicide risk for earlier intervention.
  • Rethinking antidepressant treatment – Why 50% of patients don’t respond to their first antidepressant, and how predictive modeling could reduce trial-and-error prescribing.
  • Drug development breakthroughs – How genomics and AI are identifying new targets for psychiatric drug development and improving clinical trial success rates.
  • Digital tools & biomarkers – The role of wearables, vocal biomarkers, and real-world data in improving diagnosis, treatment selection, and monitoring.
Power to the Patients is handcrafted by our friends over at: fame.so
]]> Fri, 21 Feb 2025 17:49:53 +0000 Brandon Li Brandon Li 3808 In this episode, Brandon Li sits down with Dr. Jordan Smoller - Jerrold F. Rosenbaum Chair in Psychiatry at Mass General, Co-Director for the Center for Suicide Research and Prevention at MGH and Harvard, Director of the Center for Precision Psychiatry, and a professor at Harvard Medical School, to explore the future of psychiatry. They discuss how AI, big data, and genomics are transforming mental health care—bringing us closer to precision psychiatry that moves beyond trial-and-error treatment. Dr. Smoller shares his journey from early psychiatric research to leading one of the foremost centers in precision psychiatry, tackling some of the biggest challenges in mental health. Key topics include: The promise of precision psychiatry – Why psychiatry has lagged behind other fields in precision medicine, and how AI and genomics are closing the gap. AI in suicide prevention – How electronic health records and machine learning models could predict suicide risk for earlier intervention. Rethinking antidepressant treatment – Why 50% of patients don’t respond to their first antidepressant, and how predictive modeling could reduce trial-and-error prescribing. Drug development breakthroughs – How genomics and AI are identifying new targets for psychiatric drug development and improving clinical trial success rates. Digital tools & biomarkers – The role of wearables, vocal biomarkers, and real-world data in improving diagnosis, treatment selection, and monitoring. In this episode, Brandon Li sits down with Dr. Jordan Smoller - Jerrold F. Rosenbaum Chair in Psychiatry at Mass General, Co-Director for the Center for Suicide Research and Prevention at MGH and Harvard, Director of the Center for Precision Psychiatry, and a professor at Harvard Medical School, to explore the future of psychiatry. They discuss how AI, big data, and genomics are transforming mental health care—bringing us closer to precision psychiatry that moves beyond trial-and-error treatment. Dr. Smoller shares his journey from early psychiatric research to leading one of the foremost centers in precision psychiatry, tackling some of the biggest challenges in mental health. Key topics include: The promise of precision psychiatry – Why psychiatry has lagged behind other fields in precision medicine, and how AI and genomics are closing the gap. AI in suicide prevention – How electronic health records and machine learning models could predict suicide risk for earlier intervention. Rethinking antidepressant treatment – Why 50% of patients don’t respond to their first antidepressant, and how predictive modeling could reduce trial-and-error prescribing. Drug development breakthroughs – How genomics and AI are identifying new targets for psychiatric drug development and improving clinical trial success rates. Digital tools & biomarkers – The role of wearables, vocal biomarkers, and real-world data in improving diagnosis, treatment selection, and monitoring. No No From Culture to Care: The Framework of Patient Centricity https://podcasts.fame.so/e/1n2r44yn From Culture to Care: The Framework of Patient Centricity 12 No No 219977j1 How do we move from a system that treats disease to a system that cares for individuals? Dr. Anthony Yanni, Senior Vice President and Global Head of Patient Centricity at Astellas Pharma Inc, has spent his career shaping patient-centricity—and in this episode, he shares a framework for embedding it into drug development, clinical trials, and healthcare delivery. We cover:- Building a patient-focused culture—why real patient centricity is an active process, not a slogan- Bridging the gap between research and real-world care—ensuring patient input guides drug development from the start- Mental health & neuropsychiatry trials—why patient voices must be front and center in an area long overlooked- Patient burden & clinical trials—how early engagement can improve recruitment and retention- Trust in pharma—why patient relationships must be built on transparency, collaboration, and listening first Dr. Yanni also shares insights from his new book, A Bandana and a Bluebird: The Path to a Patient-Centric Healthcare System. How do we move from a system that treats disease to a system that cares for individuals? Dr. Anthony Yanni, Senior Vice President and Global Head of Patient Centricity at Astellas Pharma Inc, has spent his career shaping patient-centricity—and in this episode, he shares a framework for embedding it into drug development, clinical trials, and healthcare delivery.

We cover:
- Building a patient-focused culture—why real patient centricity is an active process, not a slogan
- Bridging the gap between research and real-world care—ensuring patient input guides drug development from the start
- Mental health & neuropsychiatry trials—why patient voices must be front and center in an area long overlooked
- Patient burden & clinical trials—how early engagement can improve recruitment and retention
- Trust in pharma—why patient relationships must be built on transparency, collaboration, and listening first

Dr. Yanni also shares insights from his new book, A Bandana and a Bluebird: The Path to a Patient-Centric Healthcare System.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Fri, 07 Feb 2025 18:17:51 +0000 Brandon Li Brandon Li 2000 How do we move from a system that treats disease to a system that cares for individuals? Dr. Anthony Yanni, Senior Vice President and Global Head of Patient Centricity at Astellas Pharma Inc, has spent his career shaping patient-centricity—and in this episode, he shares a framework for embedding it into drug development, clinical trials, and healthcare delivery. We cover:- Building a patient-focused culture—why real patient centricity is an active process, not a slogan- Bridging the gap between research and real-world care—ensuring patient input guides drug development from the start- Mental health & neuropsychiatry trials—why patient voices must be front and center in an area long overlooked- Patient burden & clinical trials—how early engagement can improve recruitment and retention- Trust in pharma—why patient relationships must be built on transparency, collaboration, and listening first Dr. Yanni also shares insights from his new book, A Bandana and a Bluebird: The Path to a Patient-Centric Healthcare System. How do we move from a system that treats disease to a system that cares for individuals? Dr. Anthony Yanni, Senior Vice President and Global Head of Patient Centricity at Astellas Pharma Inc, has spent his career shaping patient-centricity—and in this episode, he shares a framework for embedding it into drug development, clinical trials, and healthcare delivery. We cover:- Building a patient-focused culture—why real patient centricity is an active process, not a slogan- Bridging the gap between research and real-world care—ensuring patient input guides drug development from the start- Mental health & neuropsychiatry trials—why patient voices must be front and center in an area long overlooked- Patient burden & clinical trials—how early engagement can improve recruitment and retention- Trust in pharma—why patient relationships must be built on transparency, collaboration, and listening first Dr. Yanni also shares insights from his new book, A Bandana and a Bluebird: The Path to a Patient-Centric Healthcare System. No No Unraveling Mysteries of the Brain Through Neuroscience Research https://podcasts.fame.so/e/68r7ww9n Unraveling Mysteries of the Brain Through Neuroscience Research 11 No No 805rllq1 In this episode, Brandon Li sits down with Raymond Sanchez, former CMO of Cerevel, now at Bain Capital Life Sciences, to discuss the neuroscience renaissance—the explosion of new treatments, novel mechanisms, and scientific breakthroughs reshaping the future of neuropsychiatric research. Ray shares his career journey, from early psychiatry research at Yale to scaling Cerevel from 3 to 350 employees and guiding it to a $8.7B acquisition by AbbVie. Key topics include:- The neuroscience renaissance: What’s driving renewed investment and innovation in brain research. - Research in schizophrenia: How muscarinic drugs like KarXT and Emraclidine could change the treatment landscape for schizophrenia. - The challenge of clinical trials in psychiatry: Why subjective measures, variability, and rising placebo effects make trials so difficult—and why we urgently need objective biomarkers. - Parkinson’s and Alzheimer’s research: Why disease-modifying therapies are the next frontier, and what’s still missing. - Precision neuroscience: The promise of biomarkers, digital tools, and personalized medicine—and how long it might take to reach clinical practice. Ray also shares one of his hopes for the future: developing validated biomarkers that can make psychiatric trials more objective and accelerate drug approvals. In this episode, Brandon Li sits down with Raymond Sanchez, former CMO of Cerevel, now at Bain Capital Life Sciences, to discuss the neuroscience renaissance—the explosion of new treatments, novel mechanisms, and scientific breakthroughs reshaping the future of neuropsychiatric research.

Ray shares his career journey, from early psychiatry research at Yale to scaling Cerevel from 3 to 350 employees and guiding it to a $8.7B acquisition by AbbVie.

Key topics include:
- The neuroscience renaissance: What’s driving renewed investment and innovation in brain research.

- Research in schizophrenia: How muscarinic drugs like KarXT and Emraclidine could change the treatment landscape for schizophrenia.

- The challenge of clinical trials in psychiatry: Why subjective measures, variability, and rising placebo effects make trials so difficult—and why we urgently need objective biomarkers.

- Parkinson’s and Alzheimer’s research: Why disease-modifying therapies are the next frontier, and what’s still missing.

- Precision neuroscience: The promise of biomarkers, digital tools, and personalized medicine—and how long it might take to reach clinical practice.

Ray also shares one of his hopes for the future: developing validated biomarkers that can make psychiatric trials more objective and accelerate drug approvals.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 05 Feb 2025 16:31:38 +0000 Brandon Li Brandon Li 2919 In this episode, Brandon Li sits down with Raymond Sanchez, former CMO of Cerevel, now at Bain Capital Life Sciences, to discuss the neuroscience renaissance—the explosion of new treatments, novel mechanisms, and scientific breakthroughs reshaping the future of neuropsychiatric research. Ray shares his career journey, from early psychiatry research at Yale to scaling Cerevel from 3 to 350 employees and guiding it to a $8.7B acquisition by AbbVie. Key topics include:- The neuroscience renaissance: What’s driving renewed investment and innovation in brain research. - Research in schizophrenia: How muscarinic drugs like KarXT and Emraclidine could change the treatment landscape for schizophrenia. - The challenge of clinical trials in psychiatry: Why subjective measures, variability, and rising placebo effects make trials so difficult—and why we urgently need objective biomarkers. - Parkinson’s and Alzheimer’s research: Why disease-modifying therapies are the next frontier, and what’s still missing. - Precision neuroscience: The promise of biomarkers, digital tools, and personalized medicine—and how long it might take to reach clinical practice. Ray also shares one of his hopes for the future: developing validated biomarkers that can make psychiatric trials more objective and accelerate drug approvals. In this episode, Brandon Li sits down with Raymond Sanchez, former CMO of Cerevel, now at Bain Capital Life Sciences, to discuss the neuroscience renaissance—the explosion of new treatments, novel mechanisms, and scientific breakthroughs reshaping the future of neuropsychiatric research. Ray shares his career journey, from early psychiatry research at Yale to scaling Cerevel from 3 to 350 employees and guiding it to a $8.7B acquisition by AbbVie. Key topics include:- The neuroscience renaissance: What’s driving renewed investment and innovation in brain research. - Research in schizophrenia: How muscarinic drugs like KarXT and Emraclidine could change the treatment landscape for schizophrenia. - The challenge of clinical trials in psychiatry: Why subjective measures, variability, and rising placebo effects make trials so difficult—and why we urgently need objective biomarkers. - Parkinson’s and Alzheimer’s research: Why disease-modifying therapies are the next frontier, and what’s still missing. - Precision neuroscience: The promise of biomarkers, digital tools, and personalized medicine—and how long it might take to reach clinical practice. Ray also shares one of his hopes for the future: developing validated biomarkers that can make psychiatric trials more objective and accelerate drug approvals. No No Harnessing Precision Medicine to Redefine Psychiatric Treatment https://podcasts.fame.so/e/1833kkx8 Harnessing Precision Medicine to Redefine Psychiatric Treatment 10 No No m0jpvv90 On this episode of Power to the Patients, we are joined by Amit Etkin, Founder & CEO of Alto Neuroscience and adjunct professor at Stanford, to explore how precision psychiatry is paving the way for more tailored approaches to mental health care. Amit discusses his journey from academia to founding Alto, the role of biomarkers in advancing treatment, and Alto's work on precision psychiatric medicines for MDD. Key Takeaways: - Precision Psychiatry in Practice: Amit shares how precision psychiatry applies biological insights, such as EEG biomarkers, to better understand and treat mental health conditions. While still emerging, these tools hold promise for improving care for patients. - Biomarkers and Individualized Treatment: EEG biomarkers are being used to study how individual brain activity can guide treatment choices. Amit explains how these data-driven methods could reduce the need for trial-and-error in psychiatry. - Amit’s Shift from Academia to Industry: Leaving a tenured position at Stanford, Amit founded Alto Neuroscience to create scalable solutions for unmet needs in psychiatry. He reflects on the challenges and rewards of translating science into real-world applications. - ALTO-300, Advancing MDD Treatment: ALTO-300 is being developed as an adjunctive therapy for major depressive disorder (MDD) in patients who haven’t responded to a first-line antidepressant. By using EEG biomarkers, Alto aims to identify patients most likely to benefit, potentially improving outcomes and speeding up recovery. - The Future of Precision Psychiatry: While precision psychiatry is still an evolving field, Amit emphasizes the importance of collaboration, rigorous testing, and scalable tools to make meaningful progress in mental health care. On this episode of Power to the Patients, we are joined by Amit Etkin, Founder & CEO of Alto Neuroscience and adjunct professor at Stanford, to explore how precision psychiatry is paving the way for more tailored approaches to mental health care. Amit discusses his journey from academia to founding Alto, the role of biomarkers in advancing treatment, and Alto's work on precision psychiatric medicines for MDD.

Key Takeaways:

- Precision Psychiatry in Practice: Amit shares how precision psychiatry applies biological insights, such as EEG biomarkers, to better understand and treat mental health conditions. While still emerging, these tools hold promise for improving care for patients.

- Biomarkers and Individualized Treatment: EEG biomarkers are being used to study how individual brain activity can guide treatment choices. Amit explains how these data-driven methods could reduce the need for trial-and-error in psychiatry.

- Amit’s Shift from Academia to Industry: Leaving a tenured position at Stanford, Amit founded Alto Neuroscience to create scalable solutions for unmet needs in psychiatry. He reflects on the challenges and rewards of translating science into real-world applications.

- ALTO-300, Advancing MDD Treatment: ALTO-300 is being developed as an adjunctive therapy for major depressive disorder (MDD) in patients who haven’t responded to a first-line antidepressant. By using EEG biomarkers, Alto aims to identify patients most likely to benefit, potentially improving outcomes and speeding up recovery.

- The Future of Precision Psychiatry: While precision psychiatry is still an evolving field, Amit emphasizes the importance of collaboration, rigorous testing, and scalable tools to make meaningful progress in mental health care.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 29 Jan 2025 15:14:10 +0000 Brandon Li Brandon Li 2787 On this episode of Power to the Patients, we are joined by Amit Etkin, Founder & CEO of Alto Neuroscience and adjunct professor at Stanford, to explore how precision psychiatry is paving the way for more tailored approaches to mental health care. Amit discusses his journey from academia to founding Alto, the role of biomarkers in advancing treatment, and Alto's work on precision psychiatric medicines for MDD. Key Takeaways: - Precision Psychiatry in Practice: Amit shares how precision psychiatry applies biological insights, such as EEG biomarkers, to better understand and treat mental health conditions. While still emerging, these tools hold promise for improving care for patients. - Biomarkers and Individualized Treatment: EEG biomarkers are being used to study how individual brain activity can guide treatment choices. Amit explains how these data-driven methods could reduce the need for trial-and-error in psychiatry. - Amit’s Shift from Academia to Industry: Leaving a tenured position at Stanford, Amit founded Alto Neuroscience to create scalable solutions for unmet needs in psychiatry. He reflects on the challenges and rewards of translating science into real-world applications. - ALTO-300, Advancing MDD Treatment: ALTO-300 is being developed as an adjunctive therapy for major depressive disorder (MDD) in patients who haven’t responded to a first-line antidepressant. By using EEG biomarkers, Alto aims to identify patients most likely to benefit, potentially improving outcomes and speeding up recovery. - The Future of Precision Psychiatry: While precision psychiatry is still an evolving field, Amit emphasizes the importance of collaboration, rigorous testing, and scalable tools to make meaningful progress in mental health care. On this episode of Power to the Patients, we are joined by Amit Etkin, Founder & CEO of Alto Neuroscience and adjunct professor at Stanford, to explore how precision psychiatry is paving the way for more tailored approaches to mental health care. Amit discusses his journey from academia to founding Alto, the role of biomarkers in advancing treatment, and Alto's work on precision psychiatric medicines for MDD. Key Takeaways: - Precision Psychiatry in Practice: Amit shares how precision psychiatry applies biological insights, such as EEG biomarkers, to better understand and treat mental health conditions. While still emerging, these tools hold promise for improving care for patients. - Biomarkers and Individualized Treatment: EEG biomarkers are being used to study how individual brain activity can guide treatment choices. Amit explains how these data-driven methods could reduce the need for trial-and-error in psychiatry. - Amit’s Shift from Academia to Industry: Leaving a tenured position at Stanford, Amit founded Alto Neuroscience to create scalable solutions for unmet needs in psychiatry. He reflects on the challenges and rewards of translating science into real-world applications. - ALTO-300, Advancing MDD Treatment: ALTO-300 is being developed as an adjunctive therapy for major depressive disorder (MDD) in patients who haven’t responded to a first-line antidepressant. By using EEG biomarkers, Alto aims to identify patients most likely to benefit, potentially improving outcomes and speeding up recovery. - The Future of Precision Psychiatry: While precision psychiatry is still an evolving field, Amit emphasizes the importance of collaboration, rigorous testing, and scalable tools to make meaningful progress in mental health care. No No Breaking New Ground with Psilocybin https://podcasts.fame.so/e/286q777n Breaking New Ground with Psilocybin 9 No No j12rmmm1 In this episode, Brandon Li speaks with Kabir Nath, CEO of Compass Pathways, about their groundbreaking work in using psilocybin for treatment-resistant depression (TRD). Kabir shares his personal connection to mental health, the journey of Compass Pathways, and their rigorous approach to clinical trials. The discussion also delves into the broader potential of psychedelics, regulatory challenges, and the importance of patient-centric innovation. Key takeaways:- Psilocybin for TRD: Compass Pathways focuses on treatment-resistant depression, addressing a critical unmet need for patients who have not responded to traditional therapies.- Pioneering Clinical Trials: Their phase 3 trials are the largest ever conducted for psilocybin, emphasizing safety, durability of results, and robust evidence generation.- Expanding Indications: Beyond TRD, Compass is exploring the potential of psilocybin for conditions like PTSD, highlighting its versatility as a therapeutic tool.- Patient-Centered Innovation: Kabir emphasized the importance of rigorous, ethical research to build trust and ensure equitable access for vulnerable populations.- Psilocybin vs. MDMA: The conversation highlighted the pharmacological and therapeutic differences between psilocybin and MDMA.- Policy and Public Perception: Managing public hype and addressing regulatory hurdles are key to ensuring the successful integration of psychedelics into mental health care. In this episode, Brandon Li speaks with Kabir Nath, CEO of Compass Pathways, about their groundbreaking work in using psilocybin for treatment-resistant depression (TRD). Kabir shares his personal connection to mental health, the journey of Compass Pathways, and their rigorous approach to clinical trials. The discussion also delves into the broader potential of psychedelics, regulatory challenges, and the importance of patient-centric innovation.

Key takeaways:
- Psilocybin for TRD: Compass Pathways focuses on treatment-resistant depression, addressing a critical unmet need for patients who have not responded to traditional therapies.
- Pioneering Clinical Trials: Their phase 3 trials are the largest ever conducted for psilocybin, emphasizing safety, durability of results, and robust evidence generation.
- Expanding Indications: Beyond TRD, Compass is exploring the potential of psilocybin for conditions like PTSD, highlighting its versatility as a therapeutic tool.
- Patient-Centered Innovation: Kabir emphasized the importance of rigorous, ethical research to build trust and ensure equitable access for vulnerable populations.
- Psilocybin vs. MDMA: The conversation highlighted the pharmacological and therapeutic differences between psilocybin and MDMA.
- Policy and Public Perception: Managing public hype and addressing regulatory hurdles are key to ensuring the successful integration of psychedelics into mental health care.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Tue, 21 Jan 2025 16:39:41 +0000 Brandon Li Brandon Li 2928 In this episode, Brandon Li speaks with Kabir Nath, CEO of Compass Pathways, about their groundbreaking work in using psilocybin for treatment-resistant depression (TRD). Kabir shares his personal connection to mental health, the journey of Compass Pathways, and their rigorous approach to clinical trials. The discussion also delves into the broader potential of psychedelics, regulatory challenges, and the importance of patient-centric innovation. Key takeaways:- Psilocybin for TRD: Compass Pathways focuses on treatment-resistant depression, addressing a critical unmet need for patients who have not responded to traditional therapies.- Pioneering Clinical Trials: Their phase 3 trials are the largest ever conducted for psilocybin, emphasizing safety, durability of results, and robust evidence generation.- Expanding Indications: Beyond TRD, Compass is exploring the potential of psilocybin for conditions like PTSD, highlighting its versatility as a therapeutic tool.- Patient-Centered Innovation: Kabir emphasized the importance of rigorous, ethical research to build trust and ensure equitable access for vulnerable populations.- Psilocybin vs. MDMA: The conversation highlighted the pharmacological and therapeutic differences between psilocybin and MDMA.- Policy and Public Perception: Managing public hype and addressing regulatory hurdles are key to ensuring the successful integration of psychedelics into mental health care. In this episode, Brandon Li speaks with Kabir Nath, CEO of Compass Pathways, about their groundbreaking work in using psilocybin for treatment-resistant depression (TRD). Kabir shares his personal connection to mental health, the journey of Compass Pathways, and their rigorous approach to clinical trials. The discussion also delves into the broader potential of psychedelics, regulatory challenges, and the importance of patient-centric innovation. Key takeaways:- Psilocybin for TRD: Compass Pathways focuses on treatment-resistant depression, addressing a critical unmet need for patients who have not responded to traditional therapies.- Pioneering Clinical Trials: Their phase 3 trials are the largest ever conducted for psilocybin, emphasizing safety, durability of results, and robust evidence generation.- Expanding Indications: Beyond TRD, Compass is exploring the potential of psilocybin for conditions like PTSD, highlighting its versatility as a therapeutic tool.- Patient-Centered Innovation: Kabir emphasized the importance of rigorous, ethical research to build trust and ensure equitable access for vulnerable populations.- Psilocybin vs. MDMA: The conversation highlighted the pharmacological and therapeutic differences between psilocybin and MDMA.- Policy and Public Perception: Managing public hype and addressing regulatory hurdles are key to ensuring the successful integration of psychedelics into mental health care. No No Bringing the Consumer Experience to Clinical Research https://podcasts.fame.so/e/0njy6678 Bringing the Consumer Experience to Clinical Research 8 No No 40pq55w1 In this episode of Power to the Patients, Srinivas Pai sits down with Katie Baca-Motes, Co-Founder at Scripps Research Digital Trial Center, to discuss how clinical research can learn from consumer industries to create better patient experiences. They explore advancements in digital clinical trials, behavioral science, patient-centric design, and the importance of diversity and equity in research. Katie also shares her unique insights from her time at Disney and her vision for transforming clinical research into a more inclusive and engaging space.   Key Takeaways: Patient-Centric Design: Clinical research often prioritizes researcher convenience over patient experience. Katie advocates designing trials with patients as true partners, incorporating motivations beyond financial incentives, such as learning, community, and altruism. Diversity and Equity: Building diversity into clinical trials from the planning stage is essential. Katie highlights the importance of including representative voices early on and addressing barriers like geographical and digital divides. Digital as a Bridge: Digital tools are not just for convenience; they can bridge gaps in access to clinical trials for underserved populations, especially in rural areas. Learning from Consumer Industries: Drawing from her experience at Disney, Katie stresses the importance of creating a seamless and engaging experience for participants. From onboarding to returning results, every touchpoint should enhance patient trust and retention. Reducing Barriers Through Behavioural Science: Katie highlights how applying behavioral science principles, like A/B testing and understanding participant motivations, can address key drop-off points in clinical trials. This approach ensures that trials are not just functional but also participant-friendly. In this episode of Power to the Patients, Srinivas Pai sits down with Katie Baca-Motes, Co-Founder at Scripps Research Digital Trial Center, to discuss how clinical research can learn from consumer industries to create better patient experiences. They explore advancements in digital clinical trials, behavioral science, patient-centric design, and the importance of diversity and equity in research. Katie also shares her unique insights from her time at Disney and her vision for transforming clinical research into a more inclusive and engaging space.
 
Key Takeaways:
  1. Patient-Centric Design: Clinical research often prioritizes researcher convenience over patient experience. Katie advocates designing trials with patients as true partners, incorporating motivations beyond financial incentives, such as learning, community, and altruism.
  2. Diversity and Equity: Building diversity into clinical trials from the planning stage is essential. Katie highlights the importance of including representative voices early on and addressing barriers like geographical and digital divides.
  3. Digital as a Bridge: Digital tools are not just for convenience; they can bridge gaps in access to clinical trials for underserved populations, especially in rural areas.
  4. Learning from Consumer Industries: Drawing from her experience at Disney, Katie stresses the importance of creating a seamless and engaging experience for participants. From onboarding to returning results, every touchpoint should enhance patient trust and retention.
  5. Reducing Barriers Through Behavioural Science: Katie highlights how applying behavioral science principles, like A/B testing and understanding participant motivations, can address key drop-off points in clinical trials. This approach ensures that trials are not just functional but also participant-friendly.
Power to the Patients is handcrafted by our friends over at: fame.so
]]> Thu, 19 Dec 2024 14:13:20 +0000 Brandon Li Brandon Li 1460 In this episode of Power to the Patients, Srinivas Pai sits down with Katie Baca-Motes, Co-Founder at Scripps Research Digital Trial Center, to discuss how clinical research can learn from consumer industries to create better patient experiences. They explore advancements in digital clinical trials, behavioral science, patient-centric design, and the importance of diversity and equity in research. Katie also shares her unique insights from her time at Disney and her vision for transforming clinical research into a more inclusive and engaging space.   Key Takeaways: Patient-Centric Design: Clinical research often prioritizes researcher convenience over patient experience. Katie advocates designing trials with patients as true partners, incorporating motivations beyond financial incentives, such as learning, community, and altruism. Diversity and Equity: Building diversity into clinical trials from the planning stage is essential. Katie highlights the importance of including representative voices early on and addressing barriers like geographical and digital divides. Digital as a Bridge: Digital tools are not just for convenience; they can bridge gaps in access to clinical trials for underserved populations, especially in rural areas. Learning from Consumer Industries: Drawing from her experience at Disney, Katie stresses the importance of creating a seamless and engaging experience for participants. From onboarding to returning results, every touchpoint should enhance patient trust and retention. Reducing Barriers Through Behavioural Science: Katie highlights how applying behavioral science principles, like A/B testing and understanding participant motivations, can address key drop-off points in clinical trials. This approach ensures that trials are not just functional but also participant-friendly. In this episode of Power to the Patients, Srinivas Pai sits down with Katie Baca-Motes, Co-Founder at Scripps Research Digital Trial Center, to discuss how clinical research can learn from consumer industries to create better patient experiences. They explore advancements in digital clinical trials, behavioral science, patient-centric design, and the importance of diversity and equity in research. Katie also shares her unique insights from her time at Disney and her vision for transforming clinical research into a more inclusive and engaging space.   Key Takeaways: Patient-Centric Design: Clinical research often prioritizes researcher convenience over patient experience. Katie advocates designing trials with patients as true partners, incorporating motivations beyond financial incentives, such as learning, community, and altruism. Diversity and Equity: Building diversity into clinical trials from the planning stage is essential. Katie highlights the importance of including representative voices early on and addressing barriers like geographical and digital divides. Digital as a Bridge: Digital tools are not just for convenience; they can bridge gaps in access to clinical trials for underserved populations, especially in rural areas. Learning from Consumer Industries: Drawing from her experience at Disney, Katie stresses the importance of creating a seamless and engaging experience for participants. From onboarding to returning results, every touchpoint should enhance patient trust and retention. Reducing Barriers Through Behavioural Science: Katie highlights how applying behavioral science principles, like A/B testing and understanding participant motivations, can address key drop-off points in clinical trials. This approach ensures that trials are not just functional but also participant-friendly. No No A New Frontier of Psychedelic Therapies https://podcasts.fame.so/e/lnqw994n A New Frontier of Psychedelic Therapies 7 No No 81nvllx1 In this episode, Brandon Li sits down with Manish Agrawal, Co-Founder and CEO of Sunstone Therapies, to discuss the transformative role of psychedelics in cancer care and mental health.  Manish shares his journey from oncology to leading groundbreaking research in psychedelic-assisted therapy, emphasizing its profound potential to address emotional and psychological needs that traditional medicine often overlooks. Key topics include: - Manish’s career pivot: Why seeing unmet emotional needs in oncology patients inspired Manish to transition into psychedelic research. - Complexity of psychedelic therapy: How combining psychedelics with psychological support creates a unique treatment model. - Challenges in research: How subjective patient experiences challenge traditional clinical research methods. - Patient stories: Profound moments of transformation, from facing mortality to finding peace and acceptance. - The future of psychedelics in healthcare: How tailored approaches can integrate psychedelics into mainstream care while addressing stigma and operational challenges. Tune in to hear how Manish Agrawal and Sunstone Therapies are navigating this exciting frontier. In this episode, Brandon Li sits down with Manish Agrawal, Co-Founder and CEO of Sunstone Therapies, to discuss the transformative role of psychedelics in cancer care and mental health. 

Manish shares his journey from oncology to leading groundbreaking research in psychedelic-assisted therapy, emphasizing its profound potential to address emotional and psychological needs that traditional medicine often overlooks.

Key topics include:

- Manish’s career pivot: Why seeing unmet emotional needs in oncology patients inspired Manish to transition into psychedelic research.

- Complexity of psychedelic therapy: How combining psychedelics with psychological support creates a unique treatment model.

- Challenges in research: How subjective patient experiences challenge traditional clinical research methods.

- Patient stories: Profound moments of transformation, from facing mortality to finding peace and acceptance.

- The future of psychedelics in healthcare: How tailored approaches can integrate psychedelics into mainstream care while addressing stigma and operational challenges.

Tune in to hear how Manish Agrawal and Sunstone Therapies are navigating this exciting frontier.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Thu, 12 Dec 2024 17:07:28 +0000 Brandon Li Brandon Li 2134 In this episode, Brandon Li sits down with Manish Agrawal, Co-Founder and CEO of Sunstone Therapies, to discuss the transformative role of psychedelics in cancer care and mental health.  Manish shares his journey from oncology to leading groundbreaking research in psychedelic-assisted therapy, emphasizing its profound potential to address emotional and psychological needs that traditional medicine often overlooks. Key topics include: - Manish’s career pivot: Why seeing unmet emotional needs in oncology patients inspired Manish to transition into psychedelic research. - Complexity of psychedelic therapy: How combining psychedelics with psychological support creates a unique treatment model. - Challenges in research: How subjective patient experiences challenge traditional clinical research methods. - Patient stories: Profound moments of transformation, from facing mortality to finding peace and acceptance. - The future of psychedelics in healthcare: How tailored approaches can integrate psychedelics into mainstream care while addressing stigma and operational challenges. Tune in to hear how Manish Agrawal and Sunstone Therapies are navigating this exciting frontier. In this episode, Brandon Li sits down with Manish Agrawal, Co-Founder and CEO of Sunstone Therapies, to discuss the transformative role of psychedelics in cancer care and mental health.  Manish shares his journey from oncology to leading groundbreaking research in psychedelic-assisted therapy, emphasizing its profound potential to address emotional and psychological needs that traditional medicine often overlooks. Key topics include: - Manish’s career pivot: Why seeing unmet emotional needs in oncology patients inspired Manish to transition into psychedelic research. - Complexity of psychedelic therapy: How combining psychedelics with psychological support creates a unique treatment model. - Challenges in research: How subjective patient experiences challenge traditional clinical research methods. - Patient stories: Profound moments of transformation, from facing mortality to finding peace and acceptance. - The future of psychedelics in healthcare: How tailored approaches can integrate psychedelics into mainstream care while addressing stigma and operational challenges. Tune in to hear how Manish Agrawal and Sunstone Therapies are navigating this exciting frontier. No No A Pragmatic Approach to Psychedelic Drug Development https://podcasts.fame.so/e/mn4lyykn A Pragmatic Approach to Psychedelic Drug Development 6 No No x06rnnw0 In this episode, Brandon Li sits down with Srinivas Rao, Co-CEO of atai Life Sciences, for a deep dive into the pragmatic strategies shaping the future of psychedelic therapies. Srini shares how his background in engineering and neuropharmacology has informed a streamlined, patient-centric approach to drug development. Key topics include: The evolution of atai Life Sciences, from a fund to a biotech company. Innovative drug delivery approaches, like DMT oral thin films, and why simplicity and scalability matter. Balancing diverse compounds and therapeutic areas with a focused portfolio strategy. Advancing research in areas like social anxiety disorder and cognitive impairment in schizophrenia. Tackling clinical trial challenges, including the placebo effect and trial design complexities. Tune in to hear how a pragmatic lens is redefining what’s possible in neuropsychiatric drug development. In this episode, Brandon Li sits down with Srinivas Rao, Co-CEO of atai Life Sciences, for a deep dive into the pragmatic strategies shaping the future of psychedelic therapies. Srini shares how his background in engineering and neuropharmacology has informed a streamlined, patient-centric approach to drug development.

Key topics include:

  • The evolution of atai Life Sciences, from a fund to a biotech company.
  • Innovative drug delivery approaches, like DMT oral thin films, and why simplicity and scalability matter.
  • Balancing diverse compounds and therapeutic areas with a focused portfolio strategy.
  • Advancing research in areas like social anxiety disorder and cognitive impairment in schizophrenia.
  • Tackling clinical trial challenges, including the placebo effect and trial design complexities.

Tune in to hear how a pragmatic lens is redefining what’s possible in neuropsychiatric drug development.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Fri, 06 Dec 2024 14:14:06 +0000 Brandon Li Brandon Li 2986 In this episode, Brandon Li sits down with Srinivas Rao, Co-CEO of atai Life Sciences, for a deep dive into the pragmatic strategies shaping the future of psychedelic therapies. Srini shares how his background in engineering and neuropharmacology has informed a streamlined, patient-centric approach to drug development. Key topics include: The evolution of atai Life Sciences, from a fund to a biotech company. Innovative drug delivery approaches, like DMT oral thin films, and why simplicity and scalability matter. Balancing diverse compounds and therapeutic areas with a focused portfolio strategy. Advancing research in areas like social anxiety disorder and cognitive impairment in schizophrenia. Tackling clinical trial challenges, including the placebo effect and trial design complexities. Tune in to hear how a pragmatic lens is redefining what’s possible in neuropsychiatric drug development. In this episode, Brandon Li sits down with Srinivas Rao, Co-CEO of atai Life Sciences, for a deep dive into the pragmatic strategies shaping the future of psychedelic therapies. Srini shares how his background in engineering and neuropharmacology has informed a streamlined, patient-centric approach to drug development. Key topics include: The evolution of atai Life Sciences, from a fund to a biotech company. Innovative drug delivery approaches, like DMT oral thin films, and why simplicity and scalability matter. Balancing diverse compounds and therapeutic areas with a focused portfolio strategy. Advancing research in areas like social anxiety disorder and cognitive impairment in schizophrenia. Tackling clinical trial challenges, including the placebo effect and trial design complexities. Tune in to hear how a pragmatic lens is redefining what’s possible in neuropsychiatric drug development. No No Building a High Recruiting Site in Alzheimer's https://podcasts.fame.so/e/q80vww98 Building a High Recruiting Site in Alzheimer's 5 No No p0kn88y1 In this episode, Jessica Branning, President of JBran Consulting and former CEO of ClinCloud, shares her  work in creating accessible and patient-focused clinical research sites in the neuropsych space. Jessica’s journey takes us from her early days as a clinical research coordinator to founding ClinCloud, a fully remote-capable site specializing in Alzheimer’s and dementia trials. Tune in as we dive into: How technology like EMR integrations and virtual pre-screening is transforming patient recruitment. The importance of building an ecosystem of support for Alzheimer's patients and their caregivers. Key challenges and learnings in making clinical trials more accessible, including community engagement and education. Whether you’re in clinical research, patient care, or interested in the latest in neuropsychiatry trials, Jessica’s story of building a compassionate, tech-forward site is sure to inspire. In this episode, Jessica Branning, President of JBran Consulting and former CEO of ClinCloud, shares her  work in creating accessible and patient-focused clinical research sites in the neuropsych space. Jessica’s journey takes us from her early days as a clinical research coordinator to founding ClinCloud, a fully remote-capable site specializing in Alzheimer’s and dementia trials.

Tune in as we dive into:

  • How technology like EMR integrations and virtual pre-screening is transforming patient recruitment.
  • The importance of building an ecosystem of support for Alzheimer's patients and their caregivers.
  • Key challenges and learnings in making clinical trials more accessible, including community engagement and education.

Whether you’re in clinical research, patient care, or interested in the latest in neuropsychiatry trials, Jessica’s story of building a compassionate, tech-forward site is sure to inspire.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Thu, 31 Oct 2024 17:40:09 +0000 Brandon Li Brandon Li 2740 In this episode, Jessica Branning, President of JBran Consulting and former CEO of ClinCloud, shares her  work in creating accessible and patient-focused clinical research sites in the neuropsych space. Jessica’s journey takes us from her early days as a clinical research coordinator to founding ClinCloud, a fully remote-capable site specializing in Alzheimer’s and dementia trials. Tune in as we dive into: How technology like EMR integrations and virtual pre-screening is transforming patient recruitment. The importance of building an ecosystem of support for Alzheimer's patients and their caregivers. Key challenges and learnings in making clinical trials more accessible, including community engagement and education. Whether you’re in clinical research, patient care, or interested in the latest in neuropsychiatry trials, Jessica’s story of building a compassionate, tech-forward site is sure to inspire. In this episode, Jessica Branning, President of JBran Consulting and former CEO of ClinCloud, shares her  work in creating accessible and patient-focused clinical research sites in the neuropsych space. Jessica’s journey takes us from her early days as a clinical research coordinator to founding ClinCloud, a fully remote-capable site specializing in Alzheimer’s and dementia trials. Tune in as we dive into: How technology like EMR integrations and virtual pre-screening is transforming patient recruitment. The importance of building an ecosystem of support for Alzheimer's patients and their caregivers. Key challenges and learnings in making clinical trials more accessible, including community engagement and education. Whether you’re in clinical research, patient care, or interested in the latest in neuropsychiatry trials, Jessica’s story of building a compassionate, tech-forward site is sure to inspire. No No Why Beckley Psytech is Developing the Next Generation of Psychedelics https://podcasts.fame.so/e/p8m799w8 Why Beckley Psytech is Developing the Next Generation of Psychedelics 4 No No 70v5ww91 In this episode, Brandon Li sits down with Cosmo Feilding-Mellen, CEO of Beckley Psytech, to explore the groundbreaking work Beckley is doing in the world of psychedelics. Cosmo shares his journey growing up in a family immersed in psychedelic research, co-founding Beckley Psytech, and pushing the boundaries of mental health treatment with next-generation compounds like 5-MeO-DMT. Tune in to discover why Beckley Psytech is focusing on shorter, scalable psychedelic treatments for conditions like treatment-resistant depression and substance use disorders. Cosmo explains how their innovative approach aims to make these therapies more accessible while maintaining high ethical standards, balancing cutting-edge science with compassionate care. Learn about the future of psychedelics as pharmaceutical medicines, and what it takes to develop new treatments in this rapidly evolving field. In this episode, Brandon Li sits down with Cosmo Feilding-Mellen, CEO of Beckley Psytech, to explore the groundbreaking work Beckley is doing in the world of psychedelics. Cosmo shares his journey growing up in a family immersed in psychedelic research, co-founding Beckley Psytech, and pushing the boundaries of mental health treatment with next-generation compounds like 5-MeO-DMT.

Tune in to discover why Beckley Psytech is focusing on shorter, scalable psychedelic treatments for conditions like treatment-resistant depression and substance use disorders. Cosmo explains how their innovative approach aims to make these therapies more accessible while maintaining high ethical standards, balancing cutting-edge science with compassionate care. Learn about the future of psychedelics as pharmaceutical medicines, and what it takes to develop new treatments in this rapidly evolving field.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 09 Oct 2024 17:00:00 +0000 Brandon Li Brandon Li 2336 In this episode, Brandon Li sits down with Cosmo Feilding-Mellen, CEO of Beckley Psytech, to explore the groundbreaking work Beckley is doing in the world of psychedelics. Cosmo shares his journey growing up in a family immersed in psychedelic research, co-founding Beckley Psytech, and pushing the boundaries of mental health treatment with next-generation compounds like 5-MeO-DMT. Tune in to discover why Beckley Psytech is focusing on shorter, scalable psychedelic treatments for conditions like treatment-resistant depression and substance use disorders. Cosmo explains how their innovative approach aims to make these therapies more accessible while maintaining high ethical standards, balancing cutting-edge science with compassionate care. Learn about the future of psychedelics as pharmaceutical medicines, and what it takes to develop new treatments in this rapidly evolving field. In this episode, Brandon Li sits down with Cosmo Feilding-Mellen, CEO of Beckley Psytech, to explore the groundbreaking work Beckley is doing in the world of psychedelics. Cosmo shares his journey growing up in a family immersed in psychedelic research, co-founding Beckley Psytech, and pushing the boundaries of mental health treatment with next-generation compounds like 5-MeO-DMT. Tune in to discover why Beckley Psytech is focusing on shorter, scalable psychedelic treatments for conditions like treatment-resistant depression and substance use disorders. Cosmo explains how their innovative approach aims to make these therapies more accessible while maintaining high ethical standards, balancing cutting-edge science with compassionate care. Learn about the future of psychedelics as pharmaceutical medicines, and what it takes to develop new treatments in this rapidly evolving field. No No The Mental Health Epidemic in Rural America https://podcasts.fame.so/e/28xzppr8 The Mental Health Epidemic in Rural America 3 No No 60mk22q0 In this episode, we sit down with Jeff Winton, Founder and Chairman of Rural Minds, a nonprofit dedicated to advocating for mental health services in rural America. Jeff shares his deeply personal story of how a family tragedy inspired the creation of Rural Minds and sheds light on the mental health crisis in rural communities, where stigma and lack of access to care create unique challenges. He talks about his career in the biopharmaceutical industry and how it shaped his approach to advocacy. From the isolation of rural life to the growing pressure on fragile healthcare infrastructures, Jeff emphasizes the urgent need for mental health equity and offers insights into how we can better support underserved populations. Listen in to learn more about how Rural Minds is making an impact and why storytelling is central to breaking the silence surrounding mental illness in rural America. In this episode, we sit down with Jeff Winton, Founder and Chairman of Rural Minds, a nonprofit dedicated to advocating for mental health services in rural America. Jeff shares his deeply personal story of how a family tragedy inspired the creation of Rural Minds and sheds light on the mental health crisis in rural communities, where stigma and lack of access to care create unique challenges. He talks about his career in the biopharmaceutical industry and how it shaped his approach to advocacy. From the isolation of rural life to the growing pressure on fragile healthcare infrastructures, Jeff emphasizes the urgent need for mental health equity and offers insights into how we can better support underserved populations. Listen in to learn more about how Rural Minds is making an impact and why storytelling is central to breaking the silence surrounding mental illness in rural America.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Thu, 03 Oct 2024 17:30:00 +0000 Brandon Li Brandon Li 2473 In this episode, we sit down with Jeff Winton, Founder and Chairman of Rural Minds, a nonprofit dedicated to advocating for mental health services in rural America. Jeff shares his deeply personal story of how a family tragedy inspired the creation of Rural Minds and sheds light on the mental health crisis in rural communities, where stigma and lack of access to care create unique challenges. He talks about his career in the biopharmaceutical industry and how it shaped his approach to advocacy. From the isolation of rural life to the growing pressure on fragile healthcare infrastructures, Jeff emphasizes the urgent need for mental health equity and offers insights into how we can better support underserved populations. Listen in to learn more about how Rural Minds is making an impact and why storytelling is central to breaking the silence surrounding mental illness in rural America. In this episode, we sit down with Jeff Winton, Founder and Chairman of Rural Minds, a nonprofit dedicated to advocating for mental health services in rural America. Jeff shares his deeply personal story of how a family tragedy inspired the creation of Rural Minds and sheds light on the mental health crisis in rural communities, where stigma and lack of access to care create unique challenges. He talks about his career in the biopharmaceutical industry and how it shaped his approach to advocacy. From the isolation of rural life to the growing pressure on fragile healthcare infrastructures, Jeff emphasizes the urgent need for mental health equity and offers insights into how we can better support underserved populations. Listen in to learn more about how Rural Minds is making an impact and why storytelling is central to breaking the silence surrounding mental illness in rural America. No No Going All In on Psilocybin for Depression https://podcasts.fame.so/e/v85jxx7n Going All In on Psilocybin for Depression 2 No No 81q36651 In this episode, we sit down with Doug Drysdale, CEO of Cybin, to discuss the growing interest in psilocybin as a potential treatment for depression and other mental health conditions. Doug talks candidly about his initial skepticism and how the data convinced him to dive into the world of psychedelic medicine. With decades of experience in drug development, Doug shares why he believes psilocybin represents a new approach to mental health care—one that could provide alternatives to traditional treatments like SSRIs. We explore Cybin's ongoing research, the results from their recent phase two studies, and what’s next as they prepare for phase three trials. Doug also discusses the challenges of working in a field that still faces regulatory hurdles and public stigma, and how his company is navigating these complexities. This conversation is a thoughtful look at the potential of psychedelics in medicine—what's real, what's still uncertain, and what the future might hold for patients seeking new options for managing depression and anxiety. If you're curious about the science behind psilocybin or want to understand where the field of psychedelic medicine is headed, this episode offers an honest and grounded perspective from a leader in the space. In this episode, we sit down with Doug Drysdale, CEO of Cybin, to discuss the growing interest in psilocybin as a potential treatment for depression and other mental health conditions. Doug talks candidly about his initial skepticism and how the data convinced him to dive into the world of psychedelic medicine. With decades of experience in drug development, Doug shares why he believes psilocybin represents a new approach to mental health care—one that could provide alternatives to traditional treatments like SSRIs.

We explore Cybin's ongoing research, the results from their recent phase two studies, and what’s next as they prepare for phase three trials. Doug also discusses the challenges of working in a field that still faces regulatory hurdles and public stigma, and how his company is navigating these complexities.

This conversation is a thoughtful look at the potential of psychedelics in medicine—what's real, what's still uncertain, and what the future might hold for patients seeking new options for managing depression and anxiety.


If you're curious about the science behind psilocybin or want to understand where the field of psychedelic medicine is headed, this episode offers an honest and grounded perspective from a leader in the space.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Thu, 26 Sep 2024 13:30:00 +0000 Brandon Li Brandon Li 2624 In this episode, we sit down with Doug Drysdale, CEO of Cybin, to discuss the growing interest in psilocybin as a potential treatment for depression and other mental health conditions. Doug talks candidly about his initial skepticism and how the data convinced him to dive into the world of psychedelic medicine. With decades of experience in drug development, Doug shares why he believes psilocybin represents a new approach to mental health care—one that could provide alternatives to traditional treatments like SSRIs. We explore Cybin's ongoing research, the results from their recent phase two studies, and what’s next as they prepare for phase three trials. Doug also discusses the challenges of working in a field that still faces regulatory hurdles and public stigma, and how his company is navigating these complexities. This conversation is a thoughtful look at the potential of psychedelics in medicine—what's real, what's still uncertain, and what the future might hold for patients seeking new options for managing depression and anxiety. If you're curious about the science behind psilocybin or want to understand where the field of psychedelic medicine is headed, this episode offers an honest and grounded perspective from a leader in the space. In this episode, we sit down with Doug Drysdale, CEO of Cybin, to discuss the growing interest in psilocybin as a potential treatment for depression and other mental health conditions. Doug talks candidly about his initial skepticism and how the data convinced him to dive into the world of psychedelic medicine. With decades of experience in drug development, Doug shares why he believes psilocybin represents a new approach to mental health care—one that could provide alternatives to traditional treatments like SSRIs. We explore Cybin's ongoing research, the results from their recent phase two studies, and what’s next as they prepare for phase three trials. Doug also discusses the challenges of working in a field that still faces regulatory hurdles and public stigma, and how his company is navigating these complexities. This conversation is a thoughtful look at the potential of psychedelics in medicine—what's real, what's still uncertain, and what the future might hold for patients seeking new options for managing depression and anxiety. If you're curious about the science behind psilocybin or want to understand where the field of psychedelic medicine is headed, this episode offers an honest and grounded perspective from a leader in the space. No No Psychedelics and the Future of Anxiety Relief https://podcasts.fame.so/e/xn12llv8 Psychedelics and the Future of Anxiety Relief 1 No No 703rvv41 In this episode, Dr. Dan Karlin, Chief Medical Officer at MindMed, talks about the potential of psychedelic therapies, especially LSD, to help treat anxiety. He shares his personal journey through psychiatry and addiction medicine, discussing the limitations of traditional treatments and the hope that psychedelics might bring. We dive into MindMed’s research on how LSD could impact generalized anxiety disorder (GAD), with Dr. Karlin explaining how it works and the importance of therapy alongside these treatments. This insightful conversation explores how MindMed is leading the way in developing new solutions for mental health, which could change the way we treat anxiety. In this episode, Dr. Dan Karlin, Chief Medical Officer at MindMed, talks about the potential of psychedelic therapies, especially LSD, to help treat anxiety. He shares his personal journey through psychiatry and addiction medicine, discussing the limitations of traditional treatments and the hope that psychedelics might bring. We dive into MindMed’s research on how LSD could impact generalized anxiety disorder (GAD), with Dr. Karlin explaining how it works and the importance of therapy alongside these treatments. This insightful conversation explores how MindMed is leading the way in developing new solutions for mental health, which could change the way we treat anxiety.

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Thu, 19 Sep 2024 09:01:36 +0000 Brandon Li Brandon Li 2323 In this episode, Dr. Dan Karlin, Chief Medical Officer at MindMed, talks about the potential of psychedelic therapies, especially LSD, to help treat anxiety. He shares his personal journey through psychiatry and addiction medicine, discussing the limitations of traditional treatments and the hope that psychedelics might bring. We dive into MindMed’s research on how LSD could impact generalized anxiety disorder (GAD), with Dr. Karlin explaining how it works and the importance of therapy alongside these treatments. This insightful conversation explores how MindMed is leading the way in developing new solutions for mental health, which could change the way we treat anxiety. In this episode, Dr. Dan Karlin, Chief Medical Officer at MindMed, talks about the potential of psychedelic therapies, especially LSD, to help treat anxiety. He shares his personal journey through psychiatry and addiction medicine, discussing the limitations of traditional treatments and the hope that psychedelics might bring. We dive into MindMed’s research on how LSD could impact generalized anxiety disorder (GAD), with Dr. Karlin explaining how it works and the importance of therapy alongside these treatments. This insightful conversation explores how MindMed is leading the way in developing new solutions for mental health, which could change the way we treat anxiety. No No AliveAndKickn: Raising Awareness about Lynch Syndrome https://podcasts.fame.so/e/x8y7zz68 AliveAndKickn: Raising Awareness about Lynch Syndrome 0 No No l04rxx70 Today, we sit down with Robin and Dave Dubin from the AliveAndKickn Foundation, who share their inspiring journey with Lynch Syndrome. Robin explains the genetic intricacies of this hereditary cancer predisposition, emphasizing the crucial role of genetic counseling and the proactive measures taken for their children as previvors.   Dave, a three-time cancer survivor, offers an account of his experiences, shedding light on the motivations behind the foundation's establishment and the significance of patient advocacy. Together, they reveal how personal battles can transform into movements that champion patient-centric approaches in the healthcare landscape.  Topics Discussed:  (00:00:00) Introduction  (00:01:10) Robin’s background  (00:05:07) Screening for Lynch syndrome   (00:07:08) The history of the foundation and what it does   (00:09:10) The biggest challenges in raising awareness for Lynch Syndrome   (00:11:12) What is most effective in educating patients’ families on Lynch Syndrome   (00:12:25) Interacting with larger biopharma and biotech companies pursuing research in this space  (00:15:43) The vaccine for Lynch Syndrome  (00:19:29) Increasing awareness for older patients  (00:22:24) How the foundation tries to educate the clinical community  (00:26:43) The countries the foundation focuses on  (00:28:49) Helping patients communicate with their families  (00:32:46) How people can get involved and support AliveAndKickn  Links:   Robin Beth Dubin   Dave Dubin        Today, we sit down with Robin and Dave Dubin from the AliveAndKickn Foundation, who share their inspiring journey with Lynch Syndrome. Robin explains the genetic intricacies of this hereditary cancer predisposition, emphasizing the crucial role of genetic counseling and the proactive measures taken for their children as previvors.  

Dave, a three-time cancer survivor, offers an account of his experiences, shedding light on the motivations behind the foundation's establishment and the significance of patient advocacy. Together, they reveal how personal battles can transform into movements that champion patient-centric approaches in the healthcare landscape. 

Topics Discussed: 

(00:00:00) Introduction 

(00:01:10) Robin’s background 

(00:05:07) Screening for Lynch syndrome  

(00:07:08) The history of the foundation and what it does  

(00:09:10) The biggest challenges in raising awareness for Lynch Syndrome  

(00:11:12) What is most effective in educating patients’ families on Lynch Syndrome  

(00:12:25) Interacting with larger biopharma and biotech companies pursuing research in this space 

(00:15:43) The vaccine for Lynch Syndrome 

(00:19:29) Increasing awareness for older patients 

(00:22:24) How the foundation tries to educate the clinical community 

(00:26:43) The countries the foundation focuses on 

(00:28:49) Helping patients communicate with their families 

(00:32:46) How people can get involved and support AliveAndKickn 

Links:  

Robin Beth Dubin  

Dave Dubin 

 

 

 

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Fri, 14 Jun 2024 15:40:41 +0000 Brandon Li Brandon Li 2115 Today, we sit down with Robin and Dave Dubin from the AliveAndKickn Foundation, who share their inspiring journey with Lynch Syndrome. Robin explains the genetic intricacies of this hereditary cancer predisposition, emphasizing the crucial role of genetic counseling and the proactive measures taken for their children as previvors.   Dave, a three-time cancer survivor, offers an account of his experiences, shedding light on the motivations behind the foundation's establishment and the significance of patient advocacy. Together, they reveal how personal battles can transform into movements that champion patient-centric approaches in the healthcare landscape.  Topics Discussed:  (00:00:00) Introduction  (00:01:10) Robin’s background  (00:05:07) Screening for Lynch syndrome   (00:07:08) The history of the foundation and what it does   (00:09:10) The biggest challenges in raising awareness for Lynch Syndrome   (00:11:12) What is most effective in educating patients’ families on Lynch Syndrome   (00:12:25) Interacting with larger biopharma and biotech companies pursuing research in this space  (00:15:43) The vaccine for Lynch Syndrome  (00:19:29) Increasing awareness for older patients  (00:22:24) How the foundation tries to educate the clinical community  (00:26:43) The countries the foundation focuses on  (00:28:49) Helping patients communicate with their families  (00:32:46) How people can get involved and support AliveAndKickn  Links:   Robin Beth Dubin   Dave Dubin        Today, we sit down with Robin and Dave Dubin from the AliveAndKickn Foundation, who share their inspiring journey with Lynch Syndrome. Robin explains the genetic intricacies of this hereditary cancer predisposition, emphasizing the crucial role of genetic counseling and the proactive measures taken for their children as previvors.   Dave, a three-time cancer survivor, offers an account of his experiences, shedding light on the motivations behind the foundation's establishment and the significance of patient advocacy. Together, they reveal how personal battles can transform into movements that champion patient-centric approaches in the healthcare landscape.  Topics Discussed:  (00:00:00) Introduction  (00:01:10) Robin’s background  (00:05:07) Screening for Lynch syndrome   (00:07:08) The history of the foundation and what it does   (00:09:10) The biggest challenges in raising awareness for Lynch Syndrome   (00:11:12) What is most effective in educating patients’ families on Lynch Syndrome   (00:12:25) Interacting with larger biopharma and biotech companies pursuing research in this space  (00:15:43) The vaccine for Lynch Syndrome  (00:19:29) Increasing awareness for older patients  (00:22:24) How the foundation tries to educate the clinical community  (00:26:43) The countries the foundation focuses on  (00:28:49) Helping patients communicate with their families  (00:32:46) How people can get involved and support AliveAndKickn  Links:   Robin Beth Dubin   Dave Dubin        No No Empowering Patients through Digital Platforms in Clinical Trials with Sasha Sinclair https://podcasts.fame.so/e/rnklqq08 Empowering Patients through Digital Platforms in Clinical Trials with Sasha Sinclair 0 No No 70wjqqp1 In today's episode, Sasha Sinclair discusses the current challenges and emerging solutions shaping the future of patient recruitment and engagement in clinical trials. Sasha has a comprehensive background in clinical operations that allows her to share an informed perspective about how digital strategies and improved education can transform the landscape of clinical research, making it more accessible and inclusive for patients everywhere. She talks about the problem of patients not having access to trials and how to approach it, the new patient recruitment strategies she's excited about, and how the patient's journey affects the decisions made along the way.   Topics Discussed: (00:00:00) Introduction  (00:00:56) Sasha’s background and her current role  (00:02:38) Why patient recruitment is such a struggle currently  (00:03:59) The ceiling on the percentage of providers that could feasibly do research and why it's limited  (00:04:50) How to crack the problem of patients not having access  (00:06:27) What an informal exchange of knowledge is and how it works for the patient  (00:08:13) How Power's platform plugs into the broader ecosystem  (00:10:39) What modern patient recruitment means to Sasha  (00:12:19) The core components Sasha looks for in a modern patient recruitment strategy  (00:14:56) New strategies and approaches Sasha is excited about in patient recruitment strategies  (00:16:54) Piecing together tools for recruitment strategies  (00:20:06) How to think about the incremental investment to be made in recruitment  (00:23:06) The proactive versus reactive approach at the beginning of studies  (00:24:50) Understanding the patient journey and the decisions that get made as a result  (00:26:18) How to think about patient self-advocacy as a sponsor running trials  (00:27:15) How a comprehensive effort from all stakeholders could change the game in research  Links:  Sasha Sinclair    In today's episode, Sasha Sinclair discusses the current challenges and emerging solutions shaping the future of patient recruitment and engagement in clinical trials. Sasha has a comprehensive background in clinical operations that allows her to share an informed perspective about how digital strategies and improved education can transform the landscape of clinical research, making it more accessible and inclusive for patients everywhere. She talks about the problem of patients not having access to trials and how to approach it, the new patient recruitment strategies she's excited about, and how the patient's journey affects the decisions made along the way. 

 Topics Discussed:

  • (00:00:00) Introduction 
  • (00:00:56) Sasha’s background and her current role 
  • (00:02:38) Why patient recruitment is such a struggle currently 
  • (00:03:59) The ceiling on the percentage of providers that could feasibly do research and why it's limited 
  • (00:04:50) How to crack the problem of patients not having access 
  • (00:06:27) What an informal exchange of knowledge is and how it works for the patient 
  • (00:08:13) How Power's platform plugs into the broader ecosystem 
  • (00:10:39) What modern patient recruitment means to Sasha 
  • (00:12:19) The core components Sasha looks for in a modern patient recruitment strategy 
  • (00:14:56) New strategies and approaches Sasha is excited about in patient recruitment strategies 
  • (00:16:54) Piecing together tools for recruitment strategies 
  • (00:20:06) How to think about the incremental investment to be made in recruitment 
  • (00:23:06) The proactive versus reactive approach at the beginning of studies 
  • (00:24:50) Understanding the patient journey and the decisions that get made as a result 
  • (00:26:18) How to think about patient self-advocacy as a sponsor running trials 
  • (00:27:15) How a comprehensive effort from all stakeholders could change the game in research 

Links: 

Sasha Sinclair 

 

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Tue, 07 May 2024 13:29:21 +0000 Brandon Li Brandon Li 1710 In today's episode, Sasha Sinclair discusses the current challenges and emerging solutions shaping the future of patient recruitment and engagement in clinical trials. Sasha has a comprehensive background in clinical operations that allows her to share an informed perspective about how digital strategies and improved education can transform the landscape of clinical research, making it more accessible and inclusive for patients everywhere. She talks about the problem of patients not having access to trials and how to approach it, the new patient recruitment strategies she's excited about, and how the patient's journey affects the decisions made along the way.   Topics Discussed: (00:00:00) Introduction  (00:00:56) Sasha’s background and her current role  (00:02:38) Why patient recruitment is such a struggle currently  (00:03:59) The ceiling on the percentage of providers that could feasibly do research and why it's limited  (00:04:50) How to crack the problem of patients not having access  (00:06:27) What an informal exchange of knowledge is and how it works for the patient  (00:08:13) How Power's platform plugs into the broader ecosystem  (00:10:39) What modern patient recruitment means to Sasha  (00:12:19) The core components Sasha looks for in a modern patient recruitment strategy  (00:14:56) New strategies and approaches Sasha is excited about in patient recruitment strategies  (00:16:54) Piecing together tools for recruitment strategies  (00:20:06) How to think about the incremental investment to be made in recruitment  (00:23:06) The proactive versus reactive approach at the beginning of studies  (00:24:50) Understanding the patient journey and the decisions that get made as a result  (00:26:18) How to think about patient self-advocacy as a sponsor running trials  (00:27:15) How a comprehensive effort from all stakeholders could change the game in research  Links:  Sasha Sinclair    In today's episode, Sasha Sinclair discusses the current challenges and emerging solutions shaping the future of patient recruitment and engagement in clinical trials. Sasha has a comprehensive background in clinical operations that allows her to share an informed perspective about how digital strategies and improved education can transform the landscape of clinical research, making it more accessible and inclusive for patients everywhere. She talks about the problem of patients not having access to trials and how to approach it, the new patient recruitment strategies she's excited about, and how the patient's journey affects the decisions made along the way.   Topics Discussed: (00:00:00) Introduction  (00:00:56) Sasha’s background and her current role  (00:02:38) Why patient recruitment is such a struggle currently  (00:03:59) The ceiling on the percentage of providers that could feasibly do research and why it's limited  (00:04:50) How to crack the problem of patients not having access  (00:06:27) What an informal exchange of knowledge is and how it works for the patient  (00:08:13) How Power's platform plugs into the broader ecosystem  (00:10:39) What modern patient recruitment means to Sasha  (00:12:19) The core components Sasha looks for in a modern patient recruitment strategy  (00:14:56) New strategies and approaches Sasha is excited about in patient recruitment strategies  (00:16:54) Piecing together tools for recruitment strategies  (00:20:06) How to think about the incremental investment to be made in recruitment  (00:23:06) The proactive versus reactive approach at the beginning of studies  (00:24:50) Understanding the patient journey and the decisions that get made as a result  (00:26:18) How to think about patient self-advocacy as a sponsor running trials  (00:27:15) How a comprehensive effort from all stakeholders could change the game in research  Links:  Sasha Sinclair    No No Integrating Patient Experience in Clinical Trials with Farah Meghji https://podcasts.fame.so/e/489m6628 Integrating Patient Experience in Clinical Trials with Farah Meghji 0 No No v17rqqv0 How much do you know about the behind-the-scenes process of clinical trials? Our guest today, Farah Meghji, has a unique perspective on the matter through her role at Roche Canada, where patient experience sits at the heart of every stage of solution development. We're thrilled to share her insights on balancing the urgency in clinical trial development with the necessity of embedding patient experiences from the start, transforming the way we think about patient-inclusive culture. Farah also elaborates on how Roche Canada is revolutionizing patient education materials to be more accessible and user-friendly. Topics Discussed: (00:00:00) Introduction (00:00:46) What Farah’s current role entails (00:01:18) The initiatives that Farah’s team takes on  (00:02:13) The patient journey that spans R&Ds through post-marketing (00:03:36) What being the chair of the above-brand patient council entails  (00:05:19) Examples of things implemented to further the patient experience (00:06:41) The differences in patient education communication in Canada (00:07:58) How Farah thinks about the patient experience from the R&D side of things (00:13:18) Analysis of the top barriers for patients as they think about trials (00:16:06) Specific initiatives to address barriers to patients (00:19:04) Trends in where patients are going for information and how they’re using the internet to take control of their situation (00:22:40) The approaches to finding empowered patients today (00:24:20) What Power could do to have the most impact (00:31:08) How Farah hopes to see the industry evolve (00:35:32) Farah’s final thoughts for the audience Links: Farah Meghji How much do you know about the behind-the-scenes process of clinical trials? Our guest today, Farah Meghji, has a unique perspective on the matter through her role at Roche Canada, where patient experience sits at the heart of every stage of solution development. We're thrilled to share her insights on balancing the urgency in clinical trial development with the necessity of embedding patient experiences from the start, transforming the way we think about patient-inclusive culture. Farah also elaborates on how Roche Canada is revolutionizing patient education materials to be more accessible and user-friendly.

Topics Discussed:

  • (00:00:00) Introduction
  • (00:00:46) What Farah’s current role entails
  • (00:01:18) The initiatives that Farah’s team takes on 
  • (00:02:13) The patient journey that spans R&Ds through post-marketing
  • (00:03:36) What being the chair of the above-brand patient council entails 
  • (00:05:19) Examples of things implemented to further the patient experience
  • (00:06:41) The differences in patient education communication in Canada
  • (00:07:58) How Farah thinks about the patient experience from the R&D side of things
  • (00:13:18) Analysis of the top barriers for patients as they think about trials
  • (00:16:06) Specific initiatives to address barriers to patients
  • (00:19:04) Trends in where patients are going for information and how they’re using the internet to take control of their situation
  • (00:22:40) The approaches to finding empowered patients today
  • (00:24:20) What Power could do to have the most impact
  • (00:31:08) How Farah hopes to see the industry evolve
  • (00:35:32) Farah’s final thoughts for the audience

Links:

Farah Meghji

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Thu, 25 Jan 2024 14:28:51 +0000 Brandon Li Brandon Li 2210 How much do you know about the behind-the-scenes process of clinical trials? Our guest today, Farah Meghji, has a unique perspective on the matter through her role at Roche Canada, where patient experience sits at the heart of every stage of solution development. We're thrilled to share her insights on balancing the urgency in clinical trial development with the necessity of embedding patient experiences from the start, transforming the way we think about patient-inclusive culture. Farah also elaborates on how Roche Canada is revolutionizing patient education materials to be more accessible and user-friendly. Topics Discussed: (00:00:00) Introduction (00:00:46) What Farah’s current role entails (00:01:18) The initiatives that Farah’s team takes on  (00:02:13) The patient journey that spans R&Ds through post-marketing (00:03:36) What being the chair of the above-brand patient council entails  (00:05:19) Examples of things implemented to further the patient experience (00:06:41) The differences in patient education communication in Canada (00:07:58) How Farah thinks about the patient experience from the R&D side of things (00:13:18) Analysis of the top barriers for patients as they think about trials (00:16:06) Specific initiatives to address barriers to patients (00:19:04) Trends in where patients are going for information and how they’re using the internet to take control of their situation (00:22:40) The approaches to finding empowered patients today (00:24:20) What Power could do to have the most impact (00:31:08) How Farah hopes to see the industry evolve (00:35:32) Farah’s final thoughts for the audience Links: Farah Meghji How much do you know about the behind-the-scenes process of clinical trials? Our guest today, Farah Meghji, has a unique perspective on the matter through her role at Roche Canada, where patient experience sits at the heart of every stage of solution development. We're thrilled to share her insights on balancing the urgency in clinical trial development with the necessity of embedding patient experiences from the start, transforming the way we think about patient-inclusive culture. Farah also elaborates on how Roche Canada is revolutionizing patient education materials to be more accessible and user-friendly. Topics Discussed: (00:00:00) Introduction (00:00:46) What Farah’s current role entails (00:01:18) The initiatives that Farah’s team takes on  (00:02:13) The patient journey that spans R&Ds through post-marketing (00:03:36) What being the chair of the above-brand patient council entails  (00:05:19) Examples of things implemented to further the patient experience (00:06:41) The differences in patient education communication in Canada (00:07:58) How Farah thinks about the patient experience from the R&D side of things (00:13:18) Analysis of the top barriers for patients as they think about trials (00:16:06) Specific initiatives to address barriers to patients (00:19:04) Trends in where patients are going for information and how they’re using the internet to take control of their situation (00:22:40) The approaches to finding empowered patients today (00:24:20) What Power could do to have the most impact (00:31:08) How Farah hopes to see the industry evolve (00:35:32) Farah’s final thoughts for the audience Links: Farah Meghji No No Patient-first Approaches in Clinical Trials with Megan Liles https://podcasts.fame.so/e/rn741148 Patient-first Approaches in Clinical Trials with Megan Liles 0 No No k18yrry0 Explore the world of clinical trials with our guest, Megan Liles. Drawing from her 25+ years of experience, Megan offers a practical perspective on the importance of prioritizing patients in clinical trials. She discusses the role of patient advisory boards, improving access to clinical trials, and understanding the real-life impact on patients. Megan emphasizes the significance of incorporating patient-centric approaches into clinical trial design. Topics Discussed: (00:00:00) Introduction (00:01:06) Megan's background and current role (00:05:01) What goes into making patients stakeholders (00:09:03) Why clinical trials aren't already easier for patients to navigate (00:16:24) How sites and site design are part of making patients stakeholders (00:19:59) The success of and concerns about physician referrals (00:25:07) The unpredictability of clinical trials (00:27:54) What Megan thinks everyone is getting wrong today (00:29:49) Flexibility in GCPs (00:32:45) What's productive in the space of improving awareness and access to patients that should be considering clinical trials (00:38:00) Facebook as a tool (00:39:47) How a protocol has to be designed for it to be feasible for the patient's real life (00:41:12) Ideas that looked promising during the pandemic that haven't worked out Links:Megan Liles Explore the world of clinical trials with our guest, Megan Liles. Drawing from her 25+ years of experience, Megan offers a practical perspective on the importance of prioritizing patients in clinical trials. She discusses the role of patient advisory boards, improving access to clinical trials, and understanding the real-life impact on patients. Megan emphasizes the significance of incorporating patient-centric approaches into clinical trial design.

Topics Discussed:

  • (00:00:00) Introduction
  • (00:01:06) Megan's background and current role
  • (00:05:01) What goes into making patients stakeholders
  • (00:09:03) Why clinical trials aren't already easier for patients to navigate
  • (00:16:24) How sites and site design are part of making patients stakeholders
  • (00:19:59) The success of and concerns about physician referrals
  • (00:25:07) The unpredictability of clinical trials
  • (00:27:54) What Megan thinks everyone is getting wrong today
  • (00:29:49) Flexibility in GCPs
  • (00:32:45) What's productive in the space of improving awareness and access to patients that should be considering clinical trials
  • (00:38:00) Facebook as a tool
  • (00:39:47) How a protocol has to be designed for it to be feasible for the patient's real life
  • (00:41:12) Ideas that looked promising during the pandemic that haven't worked out


Links:

Megan Liles

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 27 Dec 2023 19:13:26 +0000 Brandon Li Brandon Li 2593 Explore the world of clinical trials with our guest, Megan Liles. Drawing from her 25+ years of experience, Megan offers a practical perspective on the importance of prioritizing patients in clinical trials. She discusses the role of patient advisory boards, improving access to clinical trials, and understanding the real-life impact on patients. Megan emphasizes the significance of incorporating patient-centric approaches into clinical trial design. Topics Discussed: (00:00:00) Introduction (00:01:06) Megan's background and current role (00:05:01) What goes into making patients stakeholders (00:09:03) Why clinical trials aren't already easier for patients to navigate (00:16:24) How sites and site design are part of making patients stakeholders (00:19:59) The success of and concerns about physician referrals (00:25:07) The unpredictability of clinical trials (00:27:54) What Megan thinks everyone is getting wrong today (00:29:49) Flexibility in GCPs (00:32:45) What's productive in the space of improving awareness and access to patients that should be considering clinical trials (00:38:00) Facebook as a tool (00:39:47) How a protocol has to be designed for it to be feasible for the patient's real life (00:41:12) Ideas that looked promising during the pandemic that haven't worked out Links:Megan Liles Explore the world of clinical trials with our guest, Megan Liles. Drawing from her 25+ years of experience, Megan offers a practical perspective on the importance of prioritizing patients in clinical trials. She discusses the role of patient advisory boards, improving access to clinical trials, and understanding the real-life impact on patients. Megan emphasizes the significance of incorporating patient-centric approaches into clinical trial design. Topics Discussed: (00:00:00) Introduction (00:01:06) Megan's background and current role (00:05:01) What goes into making patients stakeholders (00:09:03) Why clinical trials aren't already easier for patients to navigate (00:16:24) How sites and site design are part of making patients stakeholders (00:19:59) The success of and concerns about physician referrals (00:25:07) The unpredictability of clinical trials (00:27:54) What Megan thinks everyone is getting wrong today (00:29:49) Flexibility in GCPs (00:32:45) What's productive in the space of improving awareness and access to patients that should be considering clinical trials (00:38:00) Facebook as a tool (00:39:47) How a protocol has to be designed for it to be feasible for the patient's real life (00:41:12) Ideas that looked promising during the pandemic that haven't worked out Links:Megan Liles No No Patient-informed clinical trial development with Victoria DiBiaso, VP & Global Head Patient Informed Development & Health Value Translation at Sanofi https://podcasts.fame.so/e/1np7jjl8 Patient-informed clinical trial development with Victoria DiBiaso, VP & Global Head Patient Informed Development & Health Value Translation at Sanofi 0 No No z0r4nnz0 Today’s episode features Victoria DiBiaso from Sanofi. Victoria provides a detailed analysis of patient-informed development and the critical importance of diversity and inclusion in clinical trials. With her unique perspective stemming from her nursing background, she explains the significance of patient-centric trials and the future of healthcare.  Throughout the episode, Victoria elaborates on effective communication with patient communities, the significance of trust-building, and how understanding social determinants of health can aid in forging strong relationships with patient advisors. The episode further explores the world of drug development, from considering patient-relevant endpoints to health scales and label opportunities.    Topics Discussed:  (00:00:00) Introduction (00:00:51) Victoria’s background and how she ended up in her current role  (00:02:32) An explanation of patient-informed development  (00:03:48) The meaning of patient centricity  (00:06:13) Stumbling blocks to patient centricity  (00:08:14) What cross-industry collaboration is like  (00:09:41) Cross-industry collaboration milestones  (00:12:07) The new voice Victoria wants to bring forward  (00:16:56) How the new programs will fit into patients’ lives  (00:18:48) How to talk about clinical trials in language patients want to hear  (00:19:53) Important factors in implementing patient-centric solutions in clinical trial programs  (00:21:24) Victoria’s thinking about what parts of patient disease strategy are shareable and standardizable  (00:23:28) What the future of patient-centric clinical trials looks like  (00:25:16) What modern patient recruitment means   (00:26:53) How Victoria would change clinical trials overnight if she had a magic wand  (00:29:44) How to learn more about what Victoria is doing  Links:   Victoria DiBiaso  Today’s episode features Victoria DiBiaso from Sanofi. Victoria provides a detailed analysis of patient-informed development and the critical importance of diversity and inclusion in clinical trials. With her unique perspective stemming from her nursing background, she explains the significance of patient-centric trials and the future of healthcare. 

Throughout the episode, Victoria elaborates on effective communication with patient communities, the significance of trust-building, and how understanding social determinants of health can aid in forging strong relationships with patient advisors. The episode further explores the world of drug development, from considering patient-relevant endpoints to health scales and label opportunities.  

 Topics Discussed: 

  • (00:00:00) Introduction
  • (00:00:51) Victoria’s background and how she ended up in her current role 
  • (00:02:32) An explanation of patient-informed development 
  • (00:03:48) The meaning of patient centricity 
  • (00:06:13) Stumbling blocks to patient centricity 
  • (00:08:14) What cross-industry collaboration is like 
  • (00:09:41) Cross-industry collaboration milestones 
  • (00:12:07) The new voice Victoria wants to bring forward 
  • (00:16:56) How the new programs will fit into patients’ lives 
  • (00:18:48) How to talk about clinical trials in language patients want to hear 
  • (00:19:53) Important factors in implementing patient-centric solutions in clinical trial programs 
  • (00:21:24) Victoria’s thinking about what parts of patient disease strategy are shareable and standardizable 
  • (00:23:28) What the future of patient-centric clinical trials looks like 
  • (00:25:16) What modern patient recruitment means  
  • (00:26:53) How Victoria would change clinical trials overnight if she had a magic wand 
  • (00:29:44) How to learn more about what Victoria is doing 

Links:  

Victoria DiBiaso 

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Mon, 11 Dec 2023 13:22:05 +0000 Brandon Li Brandon Li 1824 Today’s episode features Victoria DiBiaso from Sanofi. Victoria provides a detailed analysis of patient-informed development and the critical importance of diversity and inclusion in clinical trials. With her unique perspective stemming from her nursing background, she explains the significance of patient-centric trials and the future of healthcare.  Throughout the episode, Victoria elaborates on effective communication with patient communities, the significance of trust-building, and how understanding social determinants of health can aid in forging strong relationships with patient advisors. The episode further explores the world of drug development, from considering patient-relevant endpoints to health scales and label opportunities.    Topics Discussed:  (00:00:00) Introduction (00:00:51) Victoria’s background and how she ended up in her current role  (00:02:32) An explanation of patient-informed development  (00:03:48) The meaning of patient centricity  (00:06:13) Stumbling blocks to patient centricity  (00:08:14) What cross-industry collaboration is like  (00:09:41) Cross-industry collaboration milestones  (00:12:07) The new voice Victoria wants to bring forward  (00:16:56) How the new programs will fit into patients’ lives  (00:18:48) How to talk about clinical trials in language patients want to hear  (00:19:53) Important factors in implementing patient-centric solutions in clinical trial programs  (00:21:24) Victoria’s thinking about what parts of patient disease strategy are shareable and standardizable  (00:23:28) What the future of patient-centric clinical trials looks like  (00:25:16) What modern patient recruitment means   (00:26:53) How Victoria would change clinical trials overnight if she had a magic wand  (00:29:44) How to learn more about what Victoria is doing  Links:   Victoria DiBiaso  Today’s episode features Victoria DiBiaso from Sanofi. Victoria provides a detailed analysis of patient-informed development and the critical importance of diversity and inclusion in clinical trials. With her unique perspective stemming from her nursing background, she explains the significance of patient-centric trials and the future of healthcare.  Throughout the episode, Victoria elaborates on effective communication with patient communities, the significance of trust-building, and how understanding social determinants of health can aid in forging strong relationships with patient advisors. The episode further explores the world of drug development, from considering patient-relevant endpoints to health scales and label opportunities.    Topics Discussed:  (00:00:00) Introduction (00:00:51) Victoria’s background and how she ended up in her current role  (00:02:32) An explanation of patient-informed development  (00:03:48) The meaning of patient centricity  (00:06:13) Stumbling blocks to patient centricity  (00:08:14) What cross-industry collaboration is like  (00:09:41) Cross-industry collaboration milestones  (00:12:07) The new voice Victoria wants to bring forward  (00:16:56) How the new programs will fit into patients’ lives  (00:18:48) How to talk about clinical trials in language patients want to hear  (00:19:53) Important factors in implementing patient-centric solutions in clinical trial programs  (00:21:24) Victoria’s thinking about what parts of patient disease strategy are shareable and standardizable  (00:23:28) What the future of patient-centric clinical trials looks like  (00:25:16) What modern patient recruitment means   (00:26:53) How Victoria would change clinical trials overnight if she had a magic wand  (00:29:44) How to learn more about what Victoria is doing  Links:   Victoria DiBiaso  No No Integrating patient centricity culturally and operationally, with Dr. Anthony Yanni, Sr. VP and Head of Patient Centricity at Astellas https://podcasts.fame.so/e/58z7pprn Integrating patient centricity culturally and operationally, with Dr. Anthony Yanni, Sr. VP and Head of Patient Centricity at Astellas 0 No No 81znrr41 In this episode we delve into the topic of patient centricity in clinical trials with Dr. Anthony Yanni, Senior Vice President and Global Head of Patient-Centricity at Astellas Pharma Inc. Dr. Yanni shares what patient-centricity means for him and how it is integrated both operationally and culturally at Astellas. We explore how specialized teams work collaboratively to transform patient information into practical solutions, and the conscious patient-awareness that is a fundamental part of every role at Astellas. You'll also discover some innovative programs that bring patient-centricity to life. Topics Discussed: (00:00:00) Introduction (00:00:52) Dr. Yanni’s career and how he ended up in his current role (00:02:14) What patient-centricity means to Dr. Yanni  (00:04:12) Bringing in patient-centricity as a culture  (00:06:13) Bringing interested patients into the R&D side of operations  (00:08:15) Decisions that go a different direction due to more patient-centricity  (00:10:38) How to gather impactful insights (00:12:02) Presenting to the research team (00:14:32) How clinical operations insights translate to the recruitment space (00:16:16) How behavioral science factors in (00:18:35) What the pharma industry side gets wrong about patient-centricity today (00:21:08) Quantifying the impact of a patient’s interest (00:25:15) The first things to do when taking a new company on the journey Astellas has been on (00:26:49) How to reach out to Dr. Yanni Links: Dr. Anthony Yanni In this episode we delve into the topic of patient centricity in clinical trials with Dr. Anthony Yanni, Senior Vice President and Global Head of Patient-Centricity at Astellas Pharma Inc. Dr. Yanni shares what patient-centricity means for him and how it is integrated both operationally and culturally at Astellas.

We explore how specialized teams work collaboratively to transform patient information into practical solutions, and the conscious patient-awareness that is a fundamental part of every role at Astellas. You'll also discover some innovative programs that bring patient-centricity to life.

Topics Discussed:

  • (00:00:00) Introduction
  • (00:00:52) Dr. Yanni’s career and how he ended up in his current role
  • (00:02:14) What patient-centricity means to Dr. Yanni 
  • (00:04:12) Bringing in patient-centricity as a culture 
  • (00:06:13) Bringing interested patients into the R&D side of operations 
  • (00:08:15) Decisions that go a different direction due to more patient-centricity 
  • (00:10:38) How to gather impactful insights
  • (00:12:02) Presenting to the research team
  • (00:14:32) How clinical operations insights translate to the recruitment space
  • (00:16:16) How behavioral science factors in
  • (00:18:35) What the pharma industry side gets wrong about patient-centricity today
  • (00:21:08) Quantifying the impact of a patient’s interest
  • (00:25:15) The first things to do when taking a new company on the journey Astellas has been on
  • (00:26:49) How to reach out to Dr. Yanni

Links:

Dr. Anthony Yanni

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Tue, 21 Nov 2023 17:46:24 +0000 Brandon Li Brandon Li 1660 In this episode we delve into the topic of patient centricity in clinical trials with Dr. Anthony Yanni, Senior Vice President and Global Head of Patient-Centricity at Astellas Pharma Inc. Dr. Yanni shares what patient-centricity means for him and how it is integrated both operationally and culturally at Astellas. We explore how specialized teams work collaboratively to transform patient information into practical solutions, and the conscious patient-awareness that is a fundamental part of every role at Astellas. You'll also discover some innovative programs that bring patient-centricity to life. Topics Discussed: (00:00:00) Introduction (00:00:52) Dr. Yanni’s career and how he ended up in his current role (00:02:14) What patient-centricity means to Dr. Yanni  (00:04:12) Bringing in patient-centricity as a culture  (00:06:13) Bringing interested patients into the R&D side of operations  (00:08:15) Decisions that go a different direction due to more patient-centricity  (00:10:38) How to gather impactful insights (00:12:02) Presenting to the research team (00:14:32) How clinical operations insights translate to the recruitment space (00:16:16) How behavioral science factors in (00:18:35) What the pharma industry side gets wrong about patient-centricity today (00:21:08) Quantifying the impact of a patient’s interest (00:25:15) The first things to do when taking a new company on the journey Astellas has been on (00:26:49) How to reach out to Dr. Yanni Links: Dr. Anthony Yanni In this episode we delve into the topic of patient centricity in clinical trials with Dr. Anthony Yanni, Senior Vice President and Global Head of Patient-Centricity at Astellas Pharma Inc. Dr. Yanni shares what patient-centricity means for him and how it is integrated both operationally and culturally at Astellas. We explore how specialized teams work collaboratively to transform patient information into practical solutions, and the conscious patient-awareness that is a fundamental part of every role at Astellas. You'll also discover some innovative programs that bring patient-centricity to life. Topics Discussed: (00:00:00) Introduction (00:00:52) Dr. Yanni’s career and how he ended up in his current role (00:02:14) What patient-centricity means to Dr. Yanni  (00:04:12) Bringing in patient-centricity as a culture  (00:06:13) Bringing interested patients into the R&D side of operations  (00:08:15) Decisions that go a different direction due to more patient-centricity  (00:10:38) How to gather impactful insights (00:12:02) Presenting to the research team (00:14:32) How clinical operations insights translate to the recruitment space (00:16:16) How behavioral science factors in (00:18:35) What the pharma industry side gets wrong about patient-centricity today (00:21:08) Quantifying the impact of a patient’s interest (00:25:15) The first things to do when taking a new company on the journey Astellas has been on (00:26:49) How to reach out to Dr. Yanni Links: Dr. Anthony Yanni No No Exploring Technology and Patient Engagement in Clinical Trials with Bryan Wylie https://podcasts.fame.so/e/v8wp009n Exploring Technology and Patient Engagement in Clinical Trials with Bryan Wylie 0 No No 80x2wwr0 Today’s guest is Bryan Wylie, Global and Scientific Director of Clinical Affairs, Operations, and Field. He joins today’s episode to share his thoughts about the significance of patients in the process of clinical trials and how harnessing technology can enhance the overall success of clinical trials.  This episode explores the intersection of patient-centricity, technology, and efficiency. Bryan provides valuable insights on the importance of putting patients at the heart of clinical studies and how technology is transforming the way these trials are conducted. Bryan also discusses the role of sponsors, effective pre-planning, and team collaboration in improving patient enrollment and enhancing overall trial efficiency.  Topics Discussed:  The importance of patient-centricity in clinical trials and how it contributes to the overall success of these studies.  The role of sponsors in simplifying complex scientific data for patients, thus enhancing patient interaction and participation.  The application of AI technology in clinical studies, including the concept of a safety score decipherable by patients.  The potential of technology in helping sites manage resources efficiently and tailor patient follow-ups.  The importance of effective pre-planning and team collaboration in improving patient enrollment in clinical trials.  The use of modern tools for patient education and recruitment to streamline processes and enhance efficiency.  The potential risks and mistakes sponsors might make when implementing new methods.  The challenges and solutions for patient recruitment in medical device trials.  The impact of streamlining enrollment and creating an easier application process on trial retention and diversity.  Links:  Bryan Wylie  Today’s guest is Bryan Wylie, Global and Scientific Director of Clinical Affairs, Operations, and Field. He joins today’s episode to share his thoughts about the significance of patients in the process of clinical trials and how harnessing technology can enhance the overall success of clinical trials. 

This episode explores the intersection of patient-centricity, technology, and efficiency. Bryan provides valuable insights on the importance of putting patients at the heart of clinical studies and how technology is transforming the way these trials are conducted. Bryan also discusses the role of sponsors, effective pre-planning, and team collaboration in improving patient enrollment and enhancing overall trial efficiency. 

Topics Discussed: 

  • The importance of patient-centricity in clinical trials and how it contributes to the overall success of these studies. 
  • The role of sponsors in simplifying complex scientific data for patients, thus enhancing patient interaction and participation. 
  • The application of AI technology in clinical studies, including the concept of a safety score decipherable by patients. 
  • The potential of technology in helping sites manage resources efficiently and tailor patient follow-ups. 
  • The importance of effective pre-planning and team collaboration in improving patient enrollment in clinical trials. 
  • The use of modern tools for patient education and recruitment to streamline processes and enhance efficiency. 
  • The potential risks and mistakes sponsors might make when implementing new methods. 
  • The challenges and solutions for patient recruitment in medical device trials. 
  • The impact of streamlining enrollment and creating an easier application process on trial retention and diversity. 

Links: 

Bryan Wylie 

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Tue, 17 Oct 2023 15:09:11 +0000 Brandon Li Brandon Li 1860 Today’s guest is Bryan Wylie, Global and Scientific Director of Clinical Affairs, Operations, and Field. He joins today’s episode to share his thoughts about the significance of patients in the process of clinical trials and how harnessing technology can enhance the overall success of clinical trials.  This episode explores the intersection of patient-centricity, technology, and efficiency. Bryan provides valuable insights on the importance of putting patients at the heart of clinical studies and how technology is transforming the way these trials are conducted. Bryan also discusses the role of sponsors, effective pre-planning, and team collaboration in improving patient enrollment and enhancing overall trial efficiency.  Topics Discussed:  The importance of patient-centricity in clinical trials and how it contributes to the overall success of these studies.  The role of sponsors in simplifying complex scientific data for patients, thus enhancing patient interaction and participation.  The application of AI technology in clinical studies, including the concept of a safety score decipherable by patients.  The potential of technology in helping sites manage resources efficiently and tailor patient follow-ups.  The importance of effective pre-planning and team collaboration in improving patient enrollment in clinical trials.  The use of modern tools for patient education and recruitment to streamline processes and enhance efficiency.  The potential risks and mistakes sponsors might make when implementing new methods.  The challenges and solutions for patient recruitment in medical device trials.  The impact of streamlining enrollment and creating an easier application process on trial retention and diversity.  Links:  Bryan Wylie  Today’s guest is Bryan Wylie, Global and Scientific Director of Clinical Affairs, Operations, and Field. He joins today’s episode to share his thoughts about the significance of patients in the process of clinical trials and how harnessing technology can enhance the overall success of clinical trials.  This episode explores the intersection of patient-centricity, technology, and efficiency. Bryan provides valuable insights on the importance of putting patients at the heart of clinical studies and how technology is transforming the way these trials are conducted. Bryan also discusses the role of sponsors, effective pre-planning, and team collaboration in improving patient enrollment and enhancing overall trial efficiency.  Topics Discussed:  The importance of patient-centricity in clinical trials and how it contributes to the overall success of these studies.  The role of sponsors in simplifying complex scientific data for patients, thus enhancing patient interaction and participation.  The application of AI technology in clinical studies, including the concept of a safety score decipherable by patients.  The potential of technology in helping sites manage resources efficiently and tailor patient follow-ups.  The importance of effective pre-planning and team collaboration in improving patient enrollment in clinical trials.  The use of modern tools for patient education and recruitment to streamline processes and enhance efficiency.  The potential risks and mistakes sponsors might make when implementing new methods.  The challenges and solutions for patient recruitment in medical device trials.  The impact of streamlining enrollment and creating an easier application process on trial retention and diversity.  Links:  Bryan Wylie  No No Patient advocacy with Stephanie E. Saville, Foundation Manager for the Pediatric Retinal Research Foundation https://podcasts.fame.so/e/p8ll9958 Patient advocacy with Stephanie E. Saville, Foundation Manager for the Pediatric Retinal Research Foundation 0 No No x1l6vvk1 As the dedicated Foundation Manager for the Pediatric Retinal Research Foundation (PRRF), Stephanie Saville offers a unique and enlightening perspective into the specialized area of pediatric retinal research. The PRRF is a volunteer-driven organization that focuses on rare pediatric retinal diseases, offering support for children and adults who experience vision loss.Throughout our conversation, Stephanie emphasized the challenges rare diseases face and explored the complexities of rare disease research. Stephanie believes in the importance of understanding the 'why' behind the diagnosis, and the power of patient stories in driving change. Stephanie offers insights on how organizations can work with advocacy groups like the PRRF to drive change together. This is a must-listen episode for anyone interested in rare disease advocacy, and the power of patient stories.   Topics Discussed: An introduction to Stephanie Seville, the Foundation Manager for the Pediatric Retinal ResearchFoundation (PRRF), and an overview of the organization's focus on rare pediatric retinal diseases The volunteer-driven nature of the foundation Where Stephanie sees progress coming from and next steps in the journey The importance of the foundation’s biobank in understanding and finding the cause of rare pediatric diseases, and the challenges faced in this field such as funding and research complexity The intricacies of rare disease research, and the potential roles of pharma, biotech companies, and other organizations in supporting these initiatives The concept of "power to the patients" in the rare disease space, and the need for patients to be their own advocates and share their stories The importance of inclusivity and access in clinical trials, and how these can be ensured for patients with rare diseases   Links:  Stephanie E. Saville  Pediatric Retinal Research Foundation  As the dedicated Foundation Manager for the Pediatric Retinal Research Foundation (PRRF), Stephanie Saville offers a unique and enlightening perspective into the specialized area of pediatric retinal research. The PRRF is a volunteer-driven organization that focuses on rare pediatric retinal diseases, offering support for children and adults who experience vision loss.Throughout our conversation, Stephanie emphasized the challenges rare diseases face and explored the complexities of rare disease research.

Stephanie believes in the importance of understanding the 'why' behind the diagnosis, and the power of patient stories in driving change. Stephanie offers insights on how organizations can work with advocacy groups like the PRRF to drive change together.

This is a must-listen episode for anyone interested in rare disease advocacy, and the power of patient stories.

 

Topics Discussed:

  • An introduction to Stephanie Seville, the Foundation Manager for the Pediatric Retinal ResearchFoundation (PRRF), and an overview of the organization's focus on rare pediatric retinal diseases
  • The volunteer-driven nature of the foundation
  • Where Stephanie sees progress coming from and next steps in the journey
  • The importance of the foundation’s biobank in understanding and finding the cause of rare pediatric diseases, and the challenges faced in this field such as funding and research complexity
  • The intricacies of rare disease research, and the potential roles of pharma, biotech companies, and other organizations in supporting these initiatives
  • The concept of "power to the patients" in the rare disease space, and the need for patients to be their own advocates and share their stories
  • The importance of inclusivity and access in clinical trials, and how these can be ensured for patients with rare diseases

 

Links: 

Stephanie E. Saville 

Pediatric Retinal Research Foundation 

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 11 Oct 2023 15:23:18 +0000 Brandon Li Brandon Li 1582 As the dedicated Foundation Manager for the Pediatric Retinal Research Foundation (PRRF), Stephanie Saville offers a unique and enlightening perspective into the specialized area of pediatric retinal research. The PRRF is a volunteer-driven organization that focuses on rare pediatric retinal diseases, offering support for children and adults who experience vision loss.Throughout our conversation, Stephanie emphasized the challenges rare diseases face and explored the complexities of rare disease research. Stephanie believes in the importance of understanding the 'why' behind the diagnosis, and the power of patient stories in driving change. Stephanie offers insights on how organizations can work with advocacy groups like the PRRF to drive change together. This is a must-listen episode for anyone interested in rare disease advocacy, and the power of patient stories.   Topics Discussed: An introduction to Stephanie Seville, the Foundation Manager for the Pediatric Retinal ResearchFoundation (PRRF), and an overview of the organization's focus on rare pediatric retinal diseases The volunteer-driven nature of the foundation Where Stephanie sees progress coming from and next steps in the journey The importance of the foundation’s biobank in understanding and finding the cause of rare pediatric diseases, and the challenges faced in this field such as funding and research complexity The intricacies of rare disease research, and the potential roles of pharma, biotech companies, and other organizations in supporting these initiatives The concept of "power to the patients" in the rare disease space, and the need for patients to be their own advocates and share their stories The importance of inclusivity and access in clinical trials, and how these can be ensured for patients with rare diseases   Links:  Stephanie E. Saville  Pediatric Retinal Research Foundation  As the dedicated Foundation Manager for the Pediatric Retinal Research Foundation (PRRF), Stephanie Saville offers a unique and enlightening perspective into the specialized area of pediatric retinal research. The PRRF is a volunteer-driven organization that focuses on rare pediatric retinal diseases, offering support for children and adults who experience vision loss.Throughout our conversation, Stephanie emphasized the challenges rare diseases face and explored the complexities of rare disease research. Stephanie believes in the importance of understanding the 'why' behind the diagnosis, and the power of patient stories in driving change. Stephanie offers insights on how organizations can work with advocacy groups like the PRRF to drive change together. This is a must-listen episode for anyone interested in rare disease advocacy, and the power of patient stories.   Topics Discussed: An introduction to Stephanie Seville, the Foundation Manager for the Pediatric Retinal ResearchFoundation (PRRF), and an overview of the organization's focus on rare pediatric retinal diseases The volunteer-driven nature of the foundation Where Stephanie sees progress coming from and next steps in the journey The importance of the foundation’s biobank in understanding and finding the cause of rare pediatric diseases, and the challenges faced in this field such as funding and research complexity The intricacies of rare disease research, and the potential roles of pharma, biotech companies, and other organizations in supporting these initiatives The concept of "power to the patients" in the rare disease space, and the need for patients to be their own advocates and share their stories The importance of inclusivity and access in clinical trials, and how these can be ensured for patients with rare diseases   Links:  Stephanie E. Saville  Pediatric Retinal Research Foundation  No No Oncology trial strategy with Deb Kientop, VP Clinical Operations at Deka Biosciences https://podcasts.fame.so/e/xnvlpp7n Oncology trial strategy with Deb Kientop, VP Clinical Operations at Deka Biosciences 0 No No 71ypww50 In today’s healthcare landscape, the term ‘patient-centric’ has been showing up more and more. It emphasizes the importance of considering the patient’s needs, experiences, and preferences. In the realm of oncology clinical trials, patient-centricity plays a pivotal role. But achieving it isn't easy.  In this episode, our guest Deb Kientop, a pharmaceutical professional with 27+ years of experience, including research, clinical, medical affairs, strategy and management, explores the complex world of patient-centric oncology clinical trials. Deb shares her personal experiences, and provides a unique perspective on the intricacies involved in achieving patient-centricity in these trials. Tune in to explore the hurdles that exist in crafting patient-centric clinical trials, the role that collaboration plays in clinical trials, and how to dismantle barriers that deter patients from accessing clinical trials.  Topics Discussed:  Deb's personal experiences with clinical trials and how it highlights the importance of patient-centricity in oncology clinical trials. Challenges in designing patient-centric clinical trials for oncology patients due to varying patient pathways and needs. The role of patient advocacy groups and advisory boards in incorporating the patient voice into clinical trial protocol design. Practical considerations like time, effort, and potential travel that affect protocol inclusivity.  Importance of understanding data in context, technology use, and timelines when designing protocols and selecting sites.  Necessity of alignment between CRO and sponsors and the approach needed for successful clinical trials.  The critical role of collaboration among the sponsor, CRO, and investigator.  Importance of removing barriers for patients to access clinical trials and equipping patients and caregivers with the necessary information.  Logistical considerations in clinical trials, such as frequency of visits, travel assistance, and insurance coverage. Links:  Deb Kientop  In today’s healthcare landscape, the term ‘patient-centric’ has been showing up more and more. It emphasizes the importance of considering the patient’s needs, experiences, and preferences. In the realm of oncology clinical trials, patient-centricity plays a pivotal role. But achieving it isn't easy. 

In this episode, our guest Deb Kientop, a pharmaceutical professional with 27+ years of experience, including research, clinical, medical affairs, strategy and management, explores the complex world of patient-centric oncology clinical trials. Deb shares her personal experiences, and provides a unique perspective on the intricacies involved in achieving patient-centricity in these trials. Tune in to explore the hurdles that exist in crafting patient-centric clinical trials, the role that collaboration plays in clinical trials, and how to dismantle barriers that deter patients from accessing clinical trials. 

Topics Discussed: 

  • Deb's personal experiences with clinical trials and how it highlights the importance of patient-centricity in oncology clinical trials.
  • Challenges in designing patient-centric clinical trials for oncology patients due to varying patient pathways and needs.
  • The role of patient advocacy groups and advisory boards in incorporating the patient voice into clinical trial protocol design.
  • Practical considerations like time, effort, and potential travel that affect protocol inclusivity. 
  • Importance of understanding data in context, technology use, and timelines when designing protocols and selecting sites. 
  • Necessity of alignment between CRO and sponsors and the approach needed for successful clinical trials. 
  • The critical role of collaboration among the sponsor, CRO, and investigator. 
  • Importance of removing barriers for patients to access clinical trials and equipping patients and caregivers with the necessary information. 
  • Logistical considerations in clinical trials, such as frequency of visits, travel assistance, and insurance coverage.

Links: 

Deb Kientop 

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Tue, 03 Oct 2023 08:00:00 +0000 Brandon Li Brandon Li 2682 In today’s healthcare landscape, the term ‘patient-centric’ has been showing up more and more. It emphasizes the importance of considering the patient’s needs, experiences, and preferences. In the realm of oncology clinical trials, patient-centricity plays a pivotal role. But achieving it isn't easy.  In this episode, our guest Deb Kientop, a pharmaceutical professional with 27+ years of experience, including research, clinical, medical affairs, strategy and management, explores the complex world of patient-centric oncology clinical trials. Deb shares her personal experiences, and provides a unique perspective on the intricacies involved in achieving patient-centricity in these trials. Tune in to explore the hurdles that exist in crafting patient-centric clinical trials, the role that collaboration plays in clinical trials, and how to dismantle barriers that deter patients from accessing clinical trials.  Topics Discussed:  Deb's personal experiences with clinical trials and how it highlights the importance of patient-centricity in oncology clinical trials. Challenges in designing patient-centric clinical trials for oncology patients due to varying patient pathways and needs. The role of patient advocacy groups and advisory boards in incorporating the patient voice into clinical trial protocol design. Practical considerations like time, effort, and potential travel that affect protocol inclusivity.  Importance of understanding data in context, technology use, and timelines when designing protocols and selecting sites.  Necessity of alignment between CRO and sponsors and the approach needed for successful clinical trials.  The critical role of collaboration among the sponsor, CRO, and investigator.  Importance of removing barriers for patients to access clinical trials and equipping patients and caregivers with the necessary information.  Logistical considerations in clinical trials, such as frequency of visits, travel assistance, and insurance coverage. Links:  Deb Kientop  In today’s healthcare landscape, the term ‘patient-centric’ has been showing up more and more. It emphasizes the importance of considering the patient’s needs, experiences, and preferences. In the realm of oncology clinical trials, patient-centricity plays a pivotal role. But achieving it isn't easy.  In this episode, our guest Deb Kientop, a pharmaceutical professional with 27+ years of experience, including research, clinical, medical affairs, strategy and management, explores the complex world of patient-centric oncology clinical trials. Deb shares her personal experiences, and provides a unique perspective on the intricacies involved in achieving patient-centricity in these trials. Tune in to explore the hurdles that exist in crafting patient-centric clinical trials, the role that collaboration plays in clinical trials, and how to dismantle barriers that deter patients from accessing clinical trials.  Topics Discussed:  Deb's personal experiences with clinical trials and how it highlights the importance of patient-centricity in oncology clinical trials. Challenges in designing patient-centric clinical trials for oncology patients due to varying patient pathways and needs. The role of patient advocacy groups and advisory boards in incorporating the patient voice into clinical trial protocol design. Practical considerations like time, effort, and potential travel that affect protocol inclusivity.  Importance of understanding data in context, technology use, and timelines when designing protocols and selecting sites.  Necessity of alignment between CRO and sponsors and the approach needed for successful clinical trials.  The critical role of collaboration among the sponsor, CRO, and investigator.  Importance of removing barriers for patients to access clinical trials and equipping patients and caregivers with the necessary information.  Logistical considerations in clinical trials, such as frequency of visits, travel assistance, and insurance coverage. Links:  Deb Kientop  No No Patient-centered design with Scott Schliebner, former SVP at ICON https://podcasts.fame.so/e/182r4wy8 Patient-centered design with Scott Schliebner, former SVP at ICON 0 No No 20997rj0 In this episode, Scott Schliebner, a life sciences and digital health executive with experience across the biopharma, CRO, medtech, and non-profit sectors, discusses the evolution of patient-centricity. With over 30 years of experience, Scott provides insights into patient-centered design in clinical research.  The discussion also covers the necessity of using more humanizing terms for patients, the crucial balance in patient recruitment, the role of patient advocacy, and the future of the industry. Topics Discussed: Introduction to Scott Schliebner, a life sciences and digital health executive Evolution of patient involvement in clinical research Discussion on the current state of the industry and areas for improvement Introduction to Power's platform, designed to streamline interactions between patients and researchers Future developments in healthcare and the role of patient-centricity Consideration of the administrative burden of clinical trials and potential ways to accelerate the process Importance of building relationships with advocacy groups and providing a range of clinical trial opportunities for patients Closing remarks on the future of patient-centricity in clinical research, and an invitation to listeners to join the ongoing conversation Links: Scott Schliebner In this episode, Scott Schliebner, a life sciences and digital health executive with experience across the biopharma, CRO, medtech, and non-profit sectors, discusses the evolution of patient-centricity. With over 30 years of experience, Scott provides insights into patient-centered design in clinical research. 

The discussion also covers the necessity of using more humanizing terms for patients, the crucial balance in patient recruitment, the role of patient advocacy, and the future of the industry.

Topics Discussed:

  • Introduction to Scott Schliebner, a life sciences and digital health executive
  • Evolution of patient involvement in clinical research
  • Discussion on the current state of the industry and areas for improvement
  • Introduction to Power's platform, designed to streamline interactions between patients and researchers
  • Future developments in healthcare and the role of patient-centricity
  • Consideration of the administrative burden of clinical trials and potential ways to accelerate the process
  • Importance of building relationships with advocacy groups and providing a range of clinical trial opportunities for patients
  • Closing remarks on the future of patient-centricity in clinical research, and an invitation to listeners to join the ongoing conversation

Links:

Scott Schliebner

Power to the Patients is handcrafted by our friends over at: fame.so
]]> Wed, 27 Sep 2023 04:00:00 +0000 Brandon Li Brandon Li 2432 In this episode, Scott Schliebner, a life sciences and digital health executive with experience across the biopharma, CRO, medtech, and non-profit sectors, discusses the evolution of patient-centricity. With over 30 years of experience, Scott provides insights into patient-centered design in clinical research.  The discussion also covers the necessity of using more humanizing terms for patients, the crucial balance in patient recruitment, the role of patient advocacy, and the future of the industry. Topics Discussed: Introduction to Scott Schliebner, a life sciences and digital health executive Evolution of patient involvement in clinical research Discussion on the current state of the industry and areas for improvement Introduction to Power's platform, designed to streamline interactions between patients and researchers Future developments in healthcare and the role of patient-centricity Consideration of the administrative burden of clinical trials and potential ways to accelerate the process Importance of building relationships with advocacy groups and providing a range of clinical trial opportunities for patients Closing remarks on the future of patient-centricity in clinical research, and an invitation to listeners to join the ongoing conversation Links: Scott Schliebner In this episode, Scott Schliebner, a life sciences and digital health executive with experience across the biopharma, CRO, medtech, and non-profit sectors, discusses the evolution of patient-centricity. With over 30 years of experience, Scott provides insights into patient-centered design in clinical research.  The discussion also covers the necessity of using more humanizing terms for patients, the crucial balance in patient recruitment, the role of patient advocacy, and the future of the industry. Topics Discussed: Introduction to Scott Schliebner, a life sciences and digital health executive Evolution of patient involvement in clinical research Discussion on the current state of the industry and areas for improvement Introduction to Power's platform, designed to streamline interactions between patients and researchers Future developments in healthcare and the role of patient-centricity Consideration of the administrative burden of clinical trials and potential ways to accelerate the process Importance of building relationships with advocacy groups and providing a range of clinical trial opportunities for patients Closing remarks on the future of patient-centricity in clinical research, and an invitation to listeners to join the ongoing conversation Links: Scott Schliebner No No